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Summary 
Malaria is one of the most widespread infectious diseases which caused an estimated 212 million 
cases and 429,000 deaths worldwide in 2015. Today, artemisinin-based combination therapy (ACT), 
a combination of the fast-acting artemisinin with a longer lasting drug, is recommended to treat 
uncomplicated Plasmodium falciparum infections. Artemisinin is of highest antimalarial potency 
and selectivity. However, as a natural product, artemisinin and its derivatives also have drawbacks. 
In 2004 Jonathan Vennerstrom reported the development of synthetic peroxides that might 
overcome these shortcomings. A first-generation synthetic peroxide, OZ277, was registered with 
piperaquine for combination therapy in India in 2012 and the next-generation ozonide OZ439 is 
being tested in Phase IIb clinical trials in combination with piperaquine or ferroquine. The exact 
mode of action of synthetic peroxides and artemisinins, both thought to have similar modes of 
action, is not known. Recently, prolonged parasite clearance rates in patients after treatment with 
artesunate or ACTs were published, indicating a starting artemisinin resistance. Therefore, the fear 
of cross-resistance of artemisinin-resistant clinical isolates against OZ439, the leading candidate in 
the drug pipeline, overshadowed its superior properties. 
In this PhD thesis the mode of action of synthetic peroxides was further elucidated. First, I used 
monoclonal antibodies raised against the adamantane-portion of ozonides to perform subcellular 
localization studies and to identify alkylation signatures in P. falciparum. Since it was not possible 
to identify the alkylated parasite proteins with antibodies, I set up a novel approach using click 
chemistry with newly synthesized alkyne derivatives of antimalarial peroxides. Further, the 
potential of cross-resistance by an artemisinin-resistant clinical isolate to OZ439 was tested. 
I showed that alkylation of proteins by OZ277 and OZ439 takes place in the cytoplasm and other 
structures such as the nucleus and the food vacuole, in agreement with previous findings. 
Comparing the alkylation signatures of artemisinin and ozonides, I identified common targets to 
V 
 
both drugs, such as the protein PFNF54_01699. Overall, the ozonides had a larger target space than 
artemisinin. In addition, we found, that there is no cross-resistance in vitro of an artemisinin-
resistant clinical P. falciparum isolate to OZ439, indicating that OZ439 has the potential to 
circumvent artemisinin resistance. Nevertheless, larger clinical studies are needed to investigate if 
OZ439 is effective against artemisinin-resistant malarial parasites.   
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Abbreviations 
AA2   artemisinin-alkyne 2 
ACT   artemisinin-based combination therapy 
Cam3.IIC580Y  Cambodian isolate carrying a C580Y mutation 
Cam3.IR539T  Cambodian isolate carrying a R539T mutation 
deoxyAA2  deoxy-artemisinin-alkyne 2 
EMP   erythrocyte membrane protein 
IRS   indoor residual spraying 
ITNs   insecticide treated mosquito nets 
K13   Kelch 13 propeller domain 
kDa   kilodalton 
MDR1  multidrug resistant protein 1 
OZ   ozonide 
RBC   red blood cells 
Swiss TPH  Swiss Tropical and Public Health Institute 
TAMRA  6-carboxytetramethylrhodamine 
WHO  World Health Organization 
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1. Introduction 
1.1. Malaria 
Malaria is one of the most important tropical diseases as it caused an estimated 212 million cases and 
429,000 deaths worldwide in 2015 (World Health Organization (WHO) Malaria Report, 2016). The 
majority of malaria deaths (70% of the global total) affect children below the age of five, which 
means that every two minutes a child dies from malaria (WHO Malaria Report, 2016). Malaria cases 
are mostly restricted to tropical and subtropical areas, whereby the highest numbers of cases and 
deaths occur in Africa (90% and 92%, respectively in 2015), followed by South-East Asia and the 
Eastern Mediterranean Region (WHO Malaria Report, 2016). The infectious disease is caused by 
protozoan pathogens of Plasmodium spp., first discovered in 1880 by Charles Louis Alphonse 
Laveran, belonging to the phylum Apicomplexa (WHO Malaria Report 2016; Hempelmann et al., 
2013; Cox, 2010). Of the five different Plasmodium species, namely P. falciparum, P. vivax, P. 
malariae, P. ovale and P. knowlesi, that cause malaria in humans, P. falciparum leads to the most 
severe form of malaria, called malaria tropica. It was responsible for 99% of malaria deaths 
worldwide in 2015 (WHO Malaria Report 2016).  
Plasmodium falciparum has a complex life cycle including an insect vector as the first host and a 
human being as an intermediate host. During a blood meal of female mosquitoes belonging to the 
genus Anopheles, sporozoites are injected with the saliva into the human host. They penetrate blood 
vessels and enter the bloodstream where they quickly reach hepatocytes in the liver. The parasite 
divides asexually in the hepatocytes, a process called schizogony, resulting in tens of thousands of 
merozoites which are released into the bloodstream and invade red blood cells (RBCs). Inside the 
erythrocytes they develop into ring forms, trophozoites and finally schizonts. This process takes 48 
hours and is called erythrocytic schizogony. It ends with the rupture of schizonts, each containing 
16-32 merozoites, which then will invade new RBCs. A small fraction of merozoites develop into 
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male and female gametocytes, the stage infective for mosquitoes. When these are taken up during a 
blood meal, the sexual reproduction takes place in the mosquito, resulting in up to 10,000 
sporozoites which migrate to the salivary glands and can infect new human hosts (Mawson, 2013; 
Cowman et al., 2016; Phillips et al., 2017). Clinical symptoms of malaria manifest after rupture of 
infected RBCs and include fever, chills, headache, muscle aches, anemia and digestive symptoms 
(Mawson, 2013; Cowman et al. 2016).  
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1.2. Prevention and treatment of malaria 
Since malaria transmission is reported in 91 countries, prevention strategies are indispensable 
(WHO Malaria Report 2016). The main prevention strategies are vector control with insecticide 
treated mosquito nets (ITNs) and indoor residual spraying (IRS), which both effectively reduce 
malaria transmission in the African Region (WHO Malaria Report 2016, Lengeler, 2000). While it 
is estimated that ITNs are responsible for 50% of the decline in parasite prevalence among children 
2-10 years of age between 2001 and 2015 (WHO Malaria Report 2016), the impact of IRS is difficult 
to be valued because of limited randomized trial data. Nevertheless, it is assumed that IRS have a 
similar impact than ITNs (WHO Malaria Report 2016). Currently, twelfe insecticides belonging to 
four different chemical classes exist, but emerging resistance of Anopheles mosquitoes to 
insecticides is a major problem.  Therefore, efforts were undertaken to screen 4 million compounds, 
resulting in 3 new insecticides entering development primariliy to be used for ITNs (MalEra, 2017). 
Another prevention strategy is intermittent preventive treatment of malaria in pregnancy, which 
reduces perinatal mortality, and intermittent preventive treatment in infants, providing protection 
against malaria (WHO Malaria Report 2016). An up to 80% reduction of the incidence of clinical 
cases and severe malaria in children below the age of five can be achieved by seasonal 
chemoprevention of young children (3-59 months) in areas where malaria is seasonal (WHO 
Malaria Report 2016; MalEra, 2017). A further prevention strategy is the development of a vaccine. 
RTS,S/AS01 is the sole candidate having completed phase III testing and shown protection, albeit 
only partial (WHO Malaria Report 2016; Vandoolaeghe et al., 2016). After four doses, clinical 
incidence was reduced by 39% and severe malaria by 31.5% in young children 5-17months of age 
(WHO Malaria Report 2016; MalEra, 2017). Thus, chemotherapy remains a main pilar of the global 
fight against malaria. For the effective treatment of malaria, several drugs exist, with artemisinin-
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combination therapy (ACT) being the recommended first-line treatment of uncomplicated malaria 
tropica (WHO Malaria Report 2016, Phillips et al., 2017).    
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1.3. Artemisinin 
In the 1950s malaria parasites resistant to chloroquine, which was widely used to treat malaria, 
emerged, resulting in an urgent need for new drugs (Tu, 2011; 
Cowman et al., 2016).  
During the Vietnam war, the US army launched a drug 
discovery program that resulted in the development of 
mefloquine (Su et al., 2015; Kitchen et al., 2006). In China, the 
Project 523 was launched in 1967, in which more than 2,000 
Chinese herb preparations used in traditional remedies were 
investigated (Tu, 2011; Su et al., 2015). Youyou Tu and 
coworkers found, that extracts of Artemisia annua, a plant also called sweet wormwood or qinghao, 
showed promising inhibition of parasite grow. But these data were not reproducible and an intense 
review of literature was done. This resulted in the idea that the high temperatures used in the 
extraction could have destroyed the active ingredient (Tu, 2011). In 1971, a natural extract was 
found which was active against mice infected with P. berghei and monkeys infected with P. 
cynomolgi, when using lower temperatures for extraction. Clinical efficacy of this extract was also 
tested in patients infected with P. falciparum or P. vivax, showing fast disappearance of symptoms. 
In 1972 the active ingredient was isolated and called qinghaosu or artemisinin (Tu, 2011; Klayman, 
1985; Su et al., 2015). The discovery of artemisinin was appreciated in 2015 with the Nobel prize in 
physiology or medicine awarded to Youyou Tu (Su et al., 2015). Since it was found that artemisinin 
is poorly soluble in water, efforts to modify the structure were undertaken. Beside the discovery of 
dihydroartemisinin by Youyou Tu, which showed improved water-solubility and treatment 
efficacy, other artemisinin derivatives such as artesunate, artemether or arteether were synthesized 
(Tu, 2011, Su et al., 2015, White, 1994, Meshnick, 2002). Today, fixed dose ACTs are the first-line 
Figure 1 Chemical structure of artemisinin 
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treatment of uncomplicated P. falciparum infections. Thereby Coartem (consisting of artemether 
and lumefantrine) and Coarsucam (amodiaquine-and artesunate) are the main combination 
therapies used. For severe malaria tropica, intramuscular injections of artesunate are recommended 
(Anthony et al., 2012; Wells et al., 2015; White, 2008).    
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1.4. Mode of Action 
Already in 1975, the stereo-structure of artemisinin was investigated and found to be a sesquiterpene 
lactone, which differed from the structures of all perviously used antimalarial drugs, indicating a 
different mode of action (Tu, 2011; Klayman, 1985; Meshnick, 2002). When seven other 
sesquiterpene lactones isolated from A. annua, all lacking the peroxy group, were tested and found 
to be inactive, it was evident that the endoperoxide bridge was essential for antimalarial efficacy 
(Klayman, 1985). This finding was supported by the observation that only small amounts of 
radiolabeled deoxyarteether were taken up by parasites compared to radiolabeled arteether 
(Asawamahasakda et al., 1994), and by the fact that deoxyartemisinin, lacking the peroxide bridge, 
is over 1000-fold less active against P. falciparum than artemisinin (Kaiser et al., 2007). The exact 
mode of action is still discussed controversially (O`Neill et al., 2010). The iron- dependent alkylation 
hypothesis is one of the proposed modes of actions of artemisinins. It is suggested that there is a 
reductive cleavage of the peroxide bridge in artemisinins by ferrous heme or free Fe (II) derived 
from heme. The reducing agent is suggested to be released by the hemoglobin digestion which takes 
place in the food vacuole. Toxic free radicals are generated which then damage specific intracellular 
targets by alkylation (Tilley et al., 2016; O`Neill et al., 2010; Meshnick et al., 1993; Creek et al., 
2009). This mode of action model is supported by the fact that artemisinin localizes to the food 
vacuole and mitochondria, therefore direct contact of artemisinin and heme possibly takes place in 
the food vacuole (Maeno et al., 1993; Crespo et al., 2008). Further, artemisinin activity is only found 
in hemoglobin-degrading pathogens, but not in pathogens (or life-cycle stages) that do not degrade 
hemoglobin (Kaiser et al., 2007). P. falciparum young ring stages, in which hemoglobin digestion 
just began and less heme was produced, were slightly less sensitive than trophozoites or schizonts 
(Skinner et al., 1996; Ter Kuile et al., 1993; Maerki et al., 2006; Klayman, 1985; Kaiser et al., 2007). 
Also, young gametocytes, having a greater heme content, were more susceptible to artemisinins 
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than more mature gametocytes (Dechy-Cabaret et al., 2012; Kaiser et al., 2007). Sporozoites, which 
do not digest hemoglobin, are not susceptible to artemisinins (Kaiser et al., 2007). Another point, 
supporting the iron-dependent alkylation hypothesis is the finding, that the formation of carbon-
centered radicals is critical to the activity of artemisinin and that the interaction of artemisinin with 
parasite targets is irreversible (Fügi et al., 2010; Abiodun et al., 2013). Further, antimalarial 
endoperoxides appeared to react specifically with malarial proteins (Asawamahasakda et al., 1994). 
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1.5. Artemisinin Resistance 
Although artemisinin and its derivatives are highly potent and fast acting, prolonged parasite 
clearance rates in patients after treatment with artesunate or ACTs were observed along the Thai-
Cambodian border in 2006 (Noedl et al., 2008; Dondorp et al., 2009). WHO defines the “delayed 
parasite clearance” as “partial resistance” (WHO Malaria Report, 2016). Today, this type of 
artemisinin resistance has emerged in five countries in the Greater Mekong subregion, namely 
Cambodia, Myanmar, Vietnam, Lao PDR and China (WHO Malaria Report, 2016; Zaw et al., 2017; 
Paloque et al., 2016). It was found that mutations in the Kelch 13 propeller domain protein (K13) 
confer to ring-stage parasites the ability to enter a quiescent stage upon exposure to artemisinin. 
When drug pressure is removed, normal growth is reached again quickly (Ariey et al., 2014; Paloque 
et al., 2016). Several different mutations in the K13 gene were found, all having emerged 
independently, since same mutations were found in different geographic locations (Takala-Harrison 
et al., 2015). Individual point mutations in K13 were shown to be sufficient for artemisinin 
resistance by Zinc-finger-based genetic engineering of P. falciparum isolates (Straimer et al., 2015). 
Recently, K13 mutant alleles were mapped worldwide, whereby 108 non-synonymous mutations 
were identified out of 1250 P. falciparum isolates, mostly in samples obtained from Asia (Ménard et 
al., 2016). Although some K13 mutations were found in Africa, none of these had been associated 
with clinical artemisinin resistance, except one recent report of a migrant worker who showed 
delayed parasite clearance after ACT treatment (Tilley et al., 2016; Zaw et al., 2017; Ménard et al., 
2016). Since infections in patients showing delayed parasite clearance because of artemisinin 
resistance can still be cleared by the partner drug of ACTs, treatment failures of ACTs are limited to 
Asia, where resistance to several of the partner drugs of ACTs was reported. Today, partial resistance 
to mefloquine and amodiaquine, high resistance against piperaquine and little evidence of 
lumefantrine resistance was observed in Cambodia, resulting in high failure rates after ACT 
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treatment of four different ACTs in Cambodia (WHO Report, 2016; Blasco et al., 2017). The 
emergence of resistance occurs often in areas with high parasite loads, low transmission and low 
host immunity resulting in high numbers of patients having symptoms and seeking treatment 
(Talisuna et al., 2012). Therefore, reasons for the lack of artemisinin resistance in Africa could be 
the higher degree of acquired immunity because of permanent exposure to P. falciparum in endemic 
regions resulting in control of drug-resistant infection by the acquired host immunity (Blasco et al., 
2017, Tilley et al., 2016). Further the occurrence of polyclonal infections in Africa select against 
parasites resistant to drugs having reduced growth-rates (Tilley et al., 2016; Blasco et al., 2017; 
Paloque et al., 2016). In addition, high numbers of chronic asymptomatic infections result in lower 
drug pressure in Africa (Blasco et al., 2017; Tilley et al., 2016).  
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1.6. Disadvantages of Artemisinin 
Besides the problem of recently reported artemisinin resistance artemisinins are facing other 
disadvantages. Since artemisinins are natural products extracted from the leaves of A. annua, they 
are dependent on the availability of the plant (Tu, 2011). The first total synthesis of artemisinin was 
reported by Schmid and Hofheinz in 1983 (Schmid et al., 1983), followed by several other groups 
describing total or partial syntheses of artemisinin over the past decades (Wang et al., 2014). Also, a 
method to scale up artemisinin synthesis was described by Lévesque and Seeberger (Lévesque et al., 
2012), but total or partial synthesis of artemisinin is a complicated process, involves several steps 
(Avery et al., 1992), results in low yields, or includes high costs of starting material (White, 2008; 
Wang et al., 2014). Therefore, no reasonable alternative for a large-scale production is available at 
the moment. Also, efforts were undertaken to scale up plant production since artemisinin 
concentration in plants is relatively low. However, Youyou Tu and coworkers had already found 
that artemisinin is only present in leaves of the species Artemisia annua but not in other species of 
the genus Artemisia (Tu, 2011). Therefore, cultivation and processing of Artemisia annua plants 
were even reported in partnerships in India to provide sufficient artemisinin for malaria treatment 
(Kumar et al., 2005). Another possibility is breeding new varieties as reported in 2010 (Graham et 
al., 2010). Nevertheless, artemisinin and its derivatives are much more expensive than other 
antimalarial drugs; they cost, for example, 10 times more than chloroquine (White et al., 2008).  
Another disadvantage of artemisinins is their poor bioavailability. Further, their short in vivo half-
life, which results in recrudescence of parasitemia after 5 days of artemisinin monotherapy in spite 
of multiple applications, is an additional disadvantage. Since artemisinins are short-lived, reducing 
the high numbers of parasites for two asexual parasite cycles only, artemisinins are co-administered 
with longer half-life drugs (White, 2008; Tilley et al., 2016; Meshnick, 2002).  
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1.7. Synthetic peroxides 
The next generation of antimalarials must overcome the drawbacks of artemisinins such as the 
cumbersome production, the limiting pharmacokinetics, the poor bioavailability and costs. In 2004, 
Vennerstrom et al. reported the identification of synthetic peroxides, with OZ277 as development 
candidate, which overcome the disadvantages of artemisinins (Vennerstrom et al., 2004). A series of 
over 700 peroxides was synthesized and tested by a consortium consisting of Jonathan 
Vennerstrom`s group at the University of Nebraska (USA), Monash University (Australia), Swiss 
Tropical and Public Health Institute (Swiss TPH, Switzerland), Basilea Pharmaceutica AG 
(Switzerland) and F. Hoffmann-La Roche (Switzerland; Vennerstrom et al., 2004; Mäser et al., 2012). 
The synthesized peroxides showed best activity when a trioxolane heterocycle was stabilized by two 
additional ring structures, one adamantane ring and one phenyl ring. This turned out to be an ideal 
balance between a sterically hindered and a sterically unhindered peroxy oxygen atom for attack by 
iron (II) species (Vennerstrom et al., 2004).  
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1.8. OZ277 
Efficacy and pharmacokinetic properties of synthetic trioxolanes were optimized leading to the 
clinical candidate called OZ277 or arterolane. 
OZ277 is a synthetic 1,2,4-trioxolane with a 
structural simplicity and an economically feasible 
and scalable synthesis. Further, OZ277 showed, in 
contrast to artemisinin and its derivatives, superior antimalarial activity and an improved 
biopharmaceutical profile (Vennerstrom et al., 2004). But OZ277 failed in phase II clinical trials 
because of reduced plasma exposure in malaria patients compared to healthy volunteers when 
administered as monotherapy. Nevertheless, OZ277 in combination with piperaquine showed rapid 
parasite clearance with reduction of malaria symptoms, hence it was registered for antimalarial 
combination therapy in India in 2012 (Mäser et al., 2012; Patil et al, 2014).  
  
Figure 2 Chemical structure of OZ277 
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1.9. OZ439 
OZ439, also called artefenomel, is a next-generation ozonide containing a cis-8`-phenyl substituent 
in contrast to the cis-8`-alkyl group in OZ277. It was designed to provide a single-dose oral cure in 
humans and indeed, it was the first compound of all synthetic peroxides and artemisinin derivatives 
which completely cured P. berghei infected mice with a single oral dose of 20 mg/kg. Further, 
OZ439 was shown to be >50-fold more 
stable to Fe(II)-mediated degradation, 
suggesting that this is the reason for its 
prolonged plasma profiles in malaria 
patients (Charman et al., 2011). In addition, excellent prophylactic activity, superior to that of 
mefloquine, was demonstrated with OZ439 (Charman et al., 2011). Also, a rapid onset of action and 
activity against all asexual P. falciparum blood stages was shown in vitro (Charman et al., 2011; Kim 
et al., 2017). Phase I clinical trials of OZ439 showed good safety and pharmacokinetic profiles in 
healthy volunteers (Möhrle et al., 2012; McCarthy et al., 2016). Furthermore, good safety profiles 
were also observed in malaria patients in phase IIa studies (Phyo et al., 2016). OZ439 showed fast 
clearance of P. falciparum and P. vivax parasites in malaria patients and its long half-life suggests to 
use OZ439 in combination with another drug as single-dose oral cure (Phyo et al., 2016). OZ439 is 
now tested in Phase IIb clinical trials with piperaquine and additionally also in combination with 
ferroquine by Sanofi (Wells et al., 2015). 
  
Figure 3 Chemical structure of OZ439 
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1.10. Mode of Action 
Although synthetic peroxides have a different structure to artemisinin and its derivatives, except 
for the peroxide bridge, it was suggested that both have a similar mode of action (Vennerstrom et 
al., 2004; Jefford, 2001; Kaiser et al., 2007). As in artemisinin, it was found that the peroxide bridge 
is essential for antimalarial activity in OZ277 (Kaiser et al., 2007). Further, OZ277 was 1,000 fold 
more active against hemoglobin-degrading P. falciparum parasites than against parasites that do not 
degrade hemoglobin (Kaiser et al., 2007). This supports the iron-dependent alkylation hypothesis. 
The synthetic peroxides OZ277 and OZ439 were found to be active against all asexual blood stages 
of P. falciparum in vitro (Märki et al., 2006; Hofer et al., 2008; Charman et al., 2011; Kim et al., 
2017). Localization studies showed that in some parasites OZ277 localizes to the parasite cytosol and 
in some parasites to the food vacuole (Uhlemann et al., 2007). It was shown that for the activity of 
OZ277 and artemisinin the formation of carbon-centered radicals is essential (Fügi et al., 2010; Tang 
et al., 2005). Further it was found that the antimalarial properties of both, artemisinin and OZ277, 
derived from irreversible interactions with parasite targets (Fügi et al., 2010; Abiodun et al., 2013). 
Different studies showed that OZ277 activation was dependent on free iron, heme or ferrous heme 
(Creek et al., 2008; Creek et al., 2009). Together, all these facts corroborate the iron-dependent 
alkylation hypothesis.  
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1.11. Objectives 
The aim of this PhD thesis was to further elucidate the mode of action of synthetic peroxides in P. 
falciparum by combining cellular, biochemical and molecular approaches. The chronology of the 
chapters in this thesis follows the working process. 
First, monoclonal antibodies recognizing the adamantane portion of OZ277 and OZ439, which were 
kindly provided by Dr. Hugues Matile (Hoffmann-La Roche AG, Basel, Switzerland), were used to 
face the following objectives: 
- Investigate the localization of OZ277 and OZ439 in P. falciparum using monoclonal 
antibodies specific for adamantane-based antimalarials 
- Identify the alkylation signature of ozonides in parasite cultures incubated with OZ277 and 
OZ439 using the monoclonal antibodies 
Since increasing numbers of reports with prolonged parasite clearance rates following artemisinin 
treatment came up in South-East Asia, concerns arose if synthetic peroxides could overcome the 
emerging artemisinin-resistant phenotypes. Therefore, we set up the next objective: 
- Check if analogies in the chemical structure of artemisinins and ozonides result in cross-
resistance in artemisinin-resistant clinical isolates 
Next, we were looking for an alternative approach to the antibodies in order to identify the 
alkylation signature of ozonides. Prof. Dr. Jonathan Vennerstom (University of Nebraska, USA) had 
the idea to use a click chemistry approach and synthesized OZ molecules and artemisinins with an 
alkyne structure which are capable of performing click chemistry. This resulted in the following 
objective: 
- Establish the click chemistry method with the newly synthesized synthetic peroxides and 
identify the alkylation signatures of ozonides by mass spectrometry 
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Abstract 
The singular structure of artemisinin, with its embedded 1,2,4-trioxane heterocycle, has inspired 
the discovery of numerous semisynthetic artemisinin and structurally diverse synthetic peroxide 
antimalarials, including ozonides OZ277 (arterolane) and OZ439 (artefenomel). Despite the critical 
importance of artemisinin combination therapies (ACTs), the precise mode of action of peroxidic 
antimalarials is not fully understood. However, it has long been proposed that the peroxide bond in 
artemisinin and other antimalarial peroxides undergoes reductive activation by ferrous heme 
released during hemoglobin digestion to produce carbon-centered radicals that alkylate heme and 
parasite proteins.  To probe the mode of action of OZ277 and OZ439, we now describe initial studies 
with monoclonal antibodies that recognize the alkylation signature (sum of heme and protein 
alkylation) of these synthetic peroxides. Immunofluorescence experiments conducted with 
ozonide-treated parasite cultures showed that ozonide alkylation is restricted to the parasite, as no 
signal was found in the erythrocyte or its membrane.  In Western blot experiments with ozonide-
treated P. falciparum malaria parasites, distinct protein bands were observed.  Significantly, no 
protein bands were detected in parallel Western blot experiments performed with lysates from 
ozonide-treated Babesia divergens, parasites that also proliferate inside erythrocytes, but in contrast 
to P. falciparum, do not catabolize hemoglobin.  However, subsequent immunoprecipitation 
experiments with these antibodies failed to identify the P. falciparum proteins alkylated by OZ277 
and OZ439. To the best of our knowledge, this shows for the first time that antimalarial ozonides, 
like the artemisinins, alkylate proteins in P. falciparum.  
 
Keywords.  alkylation, artemisinin, immunofluorescence, monoclonal antibody, ozonide, 
Plasmodium falciparum.  
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Introduction 
The discovery of artemisinin (ART) from Artemisia annua1 gave rise to the semisynthetic 
artemisinins dihydroartemisinin (DHA), artemether (AM), and artesunate (AS), which as ART 
combination therapies (ACT), are the preferred treatment for uncomplicated Plasmodium 
falciparum malaria2 (Figure 1).  The singular structure of ART, with its embedded 1,2,4-trioxane 
heterocycle, inspired the discovery of additional semisynthetic artemisinins and structurally diverse 
synthetic peroxide antimalarials.3-6 One of these, ozonide (1,2,4-trioxolane) OZ277,7 also known as 
arterolane maleate, was introduced in 2012 to the Indian market as a combination product with 
piperaquine phosphate (Synriam®).8-10 More recently, the ‘next generation’ ozonide OZ439 
(artefenomel)11,12 has progressed to Phase IIb trials (Figure 1).  
  
 
Figure 1.  Artemisinin and ozonide structures. 
The peroxide bond in ART and antimalarial synthetic peroxides is essential for antiplasmodial 
activity,6,13 suggesting a chemistry-driven mechanism of action.  A considerable amount of data4,14-
24 demonstrates that the activity of antimalarial peroxides does not derive from reversible 
interactions with parasite targets and that the peroxide bond in ART and other antimalarial 
peroxides undergoes reductive activation by ferrous heme released during hemoglobin digestion to 
produce carbon-centered radicals that alkylate heme and parasite proteins (Figure 2). This is 
accompanied by disruption of the parasite digestive vacuole including lipid peroxidation.25-27 This 
mechanism accounts not only for the high antiplasmodial potency and specificity of peroxides, but 
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also for their weak and peroxide-bond independent activities against pathogens that do not degrade 
hemoglobin such as other protozoa, bacteria, and fungi.13,28,29  
 
 
Figure 2.  Alkylation reactions of ART and ozonides OZ277 and OZ439. 
Electron transfer from heme to the peroxide bond antibonding * orbitals of ART and antimalarial 
ozonides produces short-lived alkoxy radicals (Figure 2).  For ART, rearrangment via -scission 
forms a primary carbon-centered radical; for OZ277 and OZ439, rearrangement via -scission forms 
a secondary carbon-centered radical.  As these two ozonides have the same spiroadamantane 
substructure, they produce the same bicyclic carboxylic acid signature of ozonide alkylation – be 
that with heme or with proteins.  Since we had good success in capturing the ozonide-derived 
secondary carbon-centered radical with the stable nitroxide radical TEMPO and its analogs,7,22,30 we 
decided to capitalize on this finding and synthesized OZH04 as a potential hapten for this ozonide-
derived bicyclic carboxylic acid with OZH05 as a control (Scheme 1).  We now describe the creation 
of monoclonal antibodies to OZH04 and their application in immunofluorescence and Western blot 
experiments.  
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Results and Discussion 
Our first approach was to synthesize OZH04 by reductive amination of 7-(4-oxo-2,2,6,6-
tetramethyl-1-piperidinyloxy)bicyclo-[3.3.1]nonane-3-carboxylic acid,30 but the workup of this 
reaction was difficult, so we elected to access OZH04 by a two-step procedure (Scheme 1). Thus, 
reaction of prototypical ozonide 1 with ferrous iron in the presence of 4-((tert-
butoxycarbonyl)amino)-2,2,6,6-tetramethylpiperidinyl-1-oxyl (2) led to formation of intermediate 
3 in 26% yield.  We synthesized OZH04 as its dihydrochloride salt (92% yield) by deprotection of 
3 with HCl.  OZH05 was synthesized in 64% yield by exposing 4-acetamido-2,2,6,6-
tetramethylpiperidinyl-1-oxyl (4) to a mixture of cuprous chloride and aq. hydrogen peroxide 
according to the method of Dichtl et al.31  
 
Scheme 1.  Synthesis of N-alkoxyamines OZH04 and OZH05.  (a) Fe(OAc)2, 1:1 CH2Cl2:CH3CN, Fe(OAc)2, 35 °C, 24 h; (b) 
6N HCl, THF, rt, 12 h; (c) 50% H2O2, CuCl, acetone, rt, 12 h.  
The monoclonal antibodies OZH04-2/2 and OZH04-1/8 were raised in Naval Medical Research 
Institute (NMRI) mice injected subcutaneously with OZH04 hapten coupled to KLH (keyhole 
limpet hemocyanin). After the third boost, blood was collected and the serum was tested for the 
presence of antihapten antibodies by ELISA using BSA-conjugated OZH04 antigen to coat the 
ELISA-plates. Animals with strong immune responses were selected for fusion to PAI myeloma 
cells. 
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In order to determine if the monoclonal IgG1 antibodies raised against the OZH04 hapten were 
binding to P. falciparum parasites that had been exposed to OZ277 or OZ439, NF54 cultures were 
treated with either of the two ozonides, DHA or DMSO, and immunofluorescence experiments were 
performed. The two monoclonal antibodies OZH04-2/2 and OZH04-1/8 gave positive signals after 
incubation with parasites exposed to either OZ277 or OZ439 (Table 1, see 2 top rows). No 
immunofluorescence signals were detected with DHA-treated parasites, 0.1% DMSO or an 
unrelated IgG1 control antibody. An antibody raised against the cytosolic protein GAPDH served 
as a positive control.  
 
Table 1: Immunofluorescence experiments with P. falciparum cultures treated with 10 µg/mL OZ277, 10 µg/mL OZ439, 
10 µg/mL DHA or 0.1% DMSO for 2 h. Primary antibodies used were OZH04-2/2, OZH04-1/8, IgG1 negative control or 
GAPDH positive control. Goat-anti mouse Alexa 488 was used as secondary antibody. + indicates fluorescence and – 
indicates no fluorescence. 
Competition experiments with hapten OZH04 and control hapten OZH05 (Scheme 1) showed that 
the antibodies OZH04-1/8 and OZH04-2/2 specifically recognize the bicyclic carboxylic acid 
alkylation substructure, or alkylation signature, of ozonides OZ277and OZ439 (Table 2). 
 
Table 2: Immunofluorescence experiments with P. falciparum cultures treated with 10 µg/mL OZ277 or 0.1% DMSO for 
2 h. For competition, 33 µM of the hapten OZH04 or OZH05 were combined with the primary antibodies OZH04-2/2 
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(0.33 µM) or OZH04-1/8 (0.33 µM) and incubated at RT for 1 h. The secondary antibody was goat-anti mouse Alexa 488. 
+ indicates fluorescence; – indicates no fluorescence. 
In co-localization studies, synchronized P. falciparum trophozoites were treated with 10 µg/mL 
OZ277 or DMSO and directly labelled antibodies OZH04-2/2-Alexa 488 and GAPDH-Alexa 594 
(Figure 3a). These studies showed that OZ277 alkylation (green signal) is clearly restricted to the 
parasite, as no signal was found in the erythrocyte or its membrane. Within the parasite, OZ277 
alkylation co-localized with the cytoplasm (red signal) and to a weaker extent also with other 
structures such as the nucleus (blue signal) and the hemozoin-filled interior of the food vacuole 
(dark round structure). A similar co-localization pattern was also observed when rings and schizonts 
were treated with OZ277 (Supporting Information Figure 1). Immunofluorescence experiments 
performed with OZ antibody that was not directly labelled with Alexa, but was instead incubated 
with a secondary antibody containing the labels Alexa 488 or Alexa 594, resulted in much more 
pronounced signals in the food vacuole (dark round structure) (Figures 3b,c). The explanation for 
this phenomenon is unclear. One possibility is that the fluorescence signal of the OZ antibody 
directly labelled with Alexa dye is quenched in the food vacuole by hemozoin, a biocrystallized 
form of hematin, the latter being a well-known acceptor for energy transfer.32 
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Figure 3: Immunofluorescence studies with P. falciparum trophozoites that were treated with 10 µg/mL OZ277 for 2 h. a) 
In immunofluorescence co-localisation studies, the blood smears were fixed with 5% formaldehyde and 0.01% 
glutaraldehyde, permeabilized with 0.5% Triton-X-100 and blocked with 1% BSA in PBS for 1 h. The primary antibodies 
used were directly labelled OZH04-2/2 (Alexa 488, green signal) and GAPDH (Alexa 594, red signal).  For both, the 
exposure time was 2 s. Nuclei were stained with DAPI (blue signal, exposure time of 0.05 s). The bottom row left shows 
the merge of OZH04-2/2, GAPDH and DAPI, and on the bottom row right, the reference image (exposure of 1 s). Scale 
bar 2 µm. b) Same as a), except that unlabelled primary antibodies OZH04-2/2 were used. After 6 washes with PBS, 20 
µg/mL of the secondary antibody goat anti-mouse Alexa 488 (green signal) was incubated for 1 h at RT. The exposure time 
was 0.1 s. Nuclei were stained with DAPI (blue signal, exposure time of 0.05 s). The bottom row left shows the merge of 
OZH04-2/2 and DAPI, and the bottom row right shows the merge of OZH04-2/2 and the reference image (exposure of 1 
s). Scale bar 2 µm. 
c) Same as b), except that the secondary antibody used was goat anti-mouse Alexa 594 with an exposure of 1s (red signal). 
Previously, ultrastructural autoradiographic studies of [3H]-dihydroartemisinin-treated parasites 
have shown that the drug and its alkylation reaction products are present in the parasitophorous 
vacuole membranes, digestive vacuole membranes and mitochondria.15 Other work indicated that a 
fluorescent TAMRA OZ277 conjugate was associated with the food vacuole and the parasite 
endoplasmic reticulum,33 although in this study, fluorescence signal was derived from the parent 
ozonide, not from its alkylation products. To ascertain if ozonide alkylation localizes to specific 
parasite membranes, further studies will be required. 
Western Blot experiments demonstrated that monoclonal antibody OZH04-2/2 recognizes distinct 
P. falciparum protein bands (Figure 4a) in parasites treated with OZ277 or OZ439. This indicates 
that the two ozonides alkylate parasite proteins. Ring stages showed one prominent band at ~50 
kDa. In schizont stages, a variety of bands ranging from ~28 to ~98 kDa could be found after OZ277 
treatment. After longer film exposure times, the same pattern of bands was also observed in 
schizonts treated with OZ439. We conclude that the extent of ozonide alkylation seems to be higher 
in schizonts vs. rings, consistent with the greater hemoglobin digestion that has occurred in the 
former.  
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The same bands were also found when the concentrations of the ozonides were lowered to 100 
ng/mL, which at a parasitemia of 8-10%, corresponds to the IC99 (concentration where 99% of 
parasite growth is inhibited compared to untreated control parasites) (Supporting Information 
Figure 2). However, Western blot experiments performed at these lower ozonide concentrations 
were not practical as they required longer film exposure times, where false-positive signals can 
become an issue. Based on this, 10,000 ng/mL was found to be the most practical concentration. 
No bands could be observed in parasite cultures treated with carbaOZ277, the nonperoxidic analogue of 
OZ277 (Figure 4)13 or when uninfected erythrocytes were used (Supporting Information Figure 3). 
This data indicates that the antibody binding was specific for alkylated proteins.  
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Figure 4: Western blot with P. falciparum cultures synchronized for rings and schizonts. Cultures were treated with 10 
µg/mL OZ277, OZ439, CarbaOZ277 or a DMSO control (0.1%) for 2 h. All samples were normalized for their protein 
content. Antibody OZH04-2/2 and a film exposure time of 1 min were used. 
Additionally, no protein bands were detected in Western blot experiments performed with lysates 
from ozonide-treated Babesia divergens (Supporting Information Figure 4), parasites that also 
proliferate inside erythrocytes, but in contrast to P. falciparum, do not catabolize hemoglobin.34 This 
underscores the hemoglobin-digestion dependent activity of antimalarial peroxides. 
Heme has been shown to be an alkylation target of the antimalarial ozonides.17 Using monoclonal 
antibodies that specifically detect ozonide alkylation, we demonstrate here that ozonides OZ277 
and OZ439 also alkylate parasite proteins as revealed by distinct bands on Western blots (Figure 4), 
with the most prominent band at ~50 kDa. To the best of our knowledge, this shows for the first 
time that the ozonides, like the artemisinins, alkylate accessible proteins in P. falciparum. 
Artemisinin has previously been shown to alkylate as much as half of the food vacuole-associated 
heme15,35 but also proteins. Among the identified target proteins was the P. falciparum 
translationally controlled tumor protein (TCTP) homologue.16 Parasite redox-active flavoenzymes,36 
mitochondrial reductive activation,37 and the PfATP6, a sarcoplasmic reticulum calcium ATPase, 
have also been suggested as targets of artemisinins, although we have shown that OZ277 does not 
inhibit the latter.33 To better understand the roles that heme and protein alkylation play in the 
antimalarial activity of the ozonides OZ277 and OZ439, the distinct bands on the Western blots will 
need to be identified. However, we could not identify alkylated proteins in our 
immunoprecipitation experiments with the monoclonal antibodies OZH04-2/2 or OZH04-1/8.  We 
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suggest that the antibodies were not able to bind to the alkylated proteins under the non-denaturing 
conditions required for those experiments. Due to lack of binding of the antibodies to the native 
proteins, an alternative, antibody-independent approach using click chemistry is currently 
underway. 
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Methods 
Monoclonal antibody preparation 
Hapten OZH04 was coupled to KLH (keyhole limpet hemocyanin, Thermo Scientific 77600, Imject 
mcKLH) and BSA (bovine serum albumin, Thermo Scientific 77110 Imject BSA) respectively, by 
crosslinking with glutaraldehyde based on the method of Onica et al.38 
0.1 mL of OZH04 dissolved at 57.5 mg/mL in DMSO was mixed with 20 mg of the respective carrier 
protein in 0.2 M Na2HPO4 pH 8.0, and 1 mL of 0.2% glutaraldehyde in 0.2 M Na2HPO4 was then 
slowly added with agitation. After 1 h incubation at RT, the reaction was stopped by adding 0.25 
mL 1 M glycine pH 8.0 and dialyzed against PBS overnight. 
Naval Medical Research Institute (NMRI) mice were immunized with 100 µg subcutaneous 
injections of KLH-conjugated OZH04 emulsified in aluminum hydroxide gel (Alhydrogel-2%, 
Brenntag Biosector) containing CPGOGN as previously described.39 After the third boost, blood was 
collected and the serum was tested for the presence of antihapten antibodies by ELISA using BSA-
conjugated OZH04 antigen to coat the ELISA-plates. Animals with strong immune responses were 
selected for fusion.40 
Parasite cultivation 
P. falciparum strain NF54 (Origin: Airport, Netherlands; Provider MR4, MRA-1000) asexual blood 
stages were cultivated in a variation of the medium previously described,41-43 consisting of RPMI 
1640 supplemented with 0.5% ALBUMAX® II, 25 mM Hepes, 25 mM NaHCO3 (pH 7.3), 0.36 mM 
hypoxanthine, and 100 µg/mL neomycin. Human erythrocytes served as host cells. Cultures were 
maintained at 37 °C in an atmosphere of 3% O2, 4% CO2, and 93% N2 in humidified modular 
chambers. Fifty, ninety and ninety nine percent inhibitory concentrations (IC50, IC90 and IC99) of 
OZ277 in ng/mL against unsynchronized NF54 parasites were 0.91, 1.7 and 2.7 when determined at 
the standard parasitemia of 0.3% parasitemia.7 At about 10-30x higher parasitemia, the inhibitory 
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concentrations were found to be 10-30x higher, which is consistent with the so called "incoculum 
effect". The term refers to an increase in the amount of drug necessary to inhibit microbial growth 
with greater numbers of microorganisms per milliliter. This effect has been previously observed 
with antimalarial compounds such as chloroquine and artesunate, which show enrichment in P. 
falciparum-infected red blood cells.44,45 Also, OZ277 has been shown to partition into P. falciparum-
infected red blood cells.46 
Immunofluorescence 
P. falciparum NF54 cultures (5% (v/v) hematocrit, 8–10% parasitemia) were either synchronized 
with 5% D-sorbitol for trophozoites47 prior to treatment or used as mixed cultures. The cultures 
were treated with 10 µg/mL OZ277, 10 µg/mL OZ439 and 0.1% DMSO for 2 h. Cultures were 
washed once with PBS and pelleted RBCs were smeared on glass slides. The blood smears were fixed 
with prechilled methanol (-20°C; 100%) and blocked with 1% BSA in PBS for 1 h.  
Primary antibodies OZH04-2/2, OZH04-1/8, IgG1 (Hoffmann-La Roche AG, Basel, Switzerland) 
and GAPDH (glyceraldehyde-3-phosphate-dehydrogenase, a gift from Paola Favuzza, Swiss TPH, 
Basel, Switzerland) were incubated for 1 h at RT with concentrations of 50 µg/mL. After 6 washes 
with PBS, the secondary antibodies goat anti-mouse Alexa 488 (Invitrogen) or goat anti-rabbit Alexa 
594 (Invitrogen) were incubated with concentrations of 20 µg/mL for 1 h at RT. Control 
experiments, performed with secondary antibody only, resulted in no detectable 
immunofluorescence signals (not shown). 
For competition experiments, 33 µM of OZH04 or OZH05 were combined with the primary 
antibody OZH04-1/8 (0.33 µM) or OZH04-2/2 (0.33 µM) and incubated at RT for 1 h. As secondary 
antibody, goat anti-mouse Alexa 488 (20 µg/ml) was incubated for 1 h at RT. 
For co-localization studies, blood smears were fixed with 5% formaldehyde and 0.01% 
glutaraldehyde and permeabilized with 0.5% Triton-X-100. Both antibodies, OZH04-2/2 and 
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GAPDH, were directly labelled with Alexa Fluor 488 succinidyl ester (Life Technologies) and Alexa 
Fluor594 succinidyl ester (Life Technologies), respectively. 50 µg/ml of OZH04-2/2 directly labelled 
with Alexa 488 was incubated for 1 h at RT. After washing 6 times with PBS, 50 µg/mL of GAPDH 
directly labelled with Alexa 594 was incubated for 1 h at RT. Vectashield Hard Set with DAPI 
(Vector Laboratories) was added to all slides after washing 6 times with PBS. The slides were 
analysed with a Widefield Delta Vision core microscope based on an Olympus IX71 stand, using a 
60x/1.42NA oil objective. Basic image analysis (e.g. contrast and brightness adjustments) were done 
with ImageJ Fiji and images were analysed with deconvolution (SoftWorx 4.1.2; enhanced ratio 
aggressive; Number of cycles:10). 
Western blots 
P. falciparum lysates were prepared from NF54 cultures (5% (v/v) hematocrit, 8–10% parasitemia) 
synchronized with 5% D-sorbitol for rings and schizonts.47 Cultures were treated with 10 µg/mL 
OZ277, 10 µg/mL OZ439, 10 µg/mL CarbaOZ277 or 0.1% DMSO for 2 h. After centrifugation, pellets 
of samples were resuspended in 1.5 mL 0.1% saponin in PBS and incubated for 10 min on ice. 
Samples were washed twice with PBS and pellets were incubated for 10-15 min with 50 µL 
completed Ripa-Lysisbuffer (20 mM Tris-HCl pH 8.0, 137 mM NaCl, 10% glycerol, 1% NP40, 2 mM 
EDTA, EDTA-free protease inhibitor mixture tablets (Roche Applied Science)) on ice. After 
centrifugation, extracts were used for Western blot. For normalizing protein contents in ring- and 
schizont samples, a BCA protein assay was performed using a BCA protein assay kit from Merck 
Millipore (Product No. 21285-3) with BSA as standard prior to the Western blot.  
NP40 extracts were diluted 1:2 with 2x LDS sample buffer (50% 4x LDS sample buffer, Invitrogen; 
20% mercaptoethanol; 30% ddH2O), heated for 10 min at 70 °C, loaded onto polyacrylamide gels 
(10 µL of samples; 4-12% Bis-Tris-polyacrylamide Gels, Invitrogen) and run for 35 min (120 mA; 
200 V) using 1x MES SDS Running Buffer (20x MES DS Running Buffer, Invitrogen) as running 
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buffer. Gels were transferred onto nitrocellulose membranes (0.2 µm pore size; 100% nitrocellulose, 
Invitrogen) and blocked for 1 h with 3% milk powder blocking solution (3% milk powder in TBS-
Tween buffer pH 8.0; TBS-Tween buffer: 20 mM Tris, 150 mM NaCl, 0.05% Tween-20, pH adjusted 
to 8.0 with HCl). 1 µg/mL of OZH04-2/2 antibody, diluted in 0.5% milk powder blocking solution, 
was added to the membrane and incubated for 1 h at rt. Membranes were washed 3 times for 5 min 
with TBS- Tween buffer and incubated with polyclonal rabbit anti- mouse immunoglobulin 
horseradish peroxidase 1:5000 (1.3 g/L; DAKO; diluted in 0.5% milk powder in TBS-Tween buffer) 
for 1 h at RT. Membranes were washed 4 times for 5 min with TBS-Tween buffer. Super Signal West 
Pico Chemiluminescent Substrate (Thermo Scientific) was added to the membrane, incubated for 5 
min and the Western blot was developed using a Carestream Kodak Biomax light film (Sigma). 
 
Supporting Information.  Synthesis and characterization of OZH04 and OZH05. 
Immunofluorescence experiments with P. falciparum rings, trophozoites and schizonts treated with 
OZ277 (SI Figure 1). Western Blot experiments with mixed P. falciparum cultures treated with a range 
of OZ277 concentrations (SI Figure 2). Western blot and Coomassie gel for uninfected erythrocytes (SI 
Figure 3) or Babesia divergens (SI Figure 4) treated with OZ277, OZ439, CarbaOZ277 or a DMSO 
control. This material is available free of charge via the Internet at http://pubs.acs.org.  
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DMSO, dimethyl sulfoxide; ELISA, enzyme linked immunosorbent assay; GAPDH, glyceraldehyde 
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SUPPORTING INFORMATION 
Synthesis and characterization of OZH04 and OZH05. 
Melting points are uncorrected. 1H and 13C NMR spectra were recorded on a 500 MHz spectrometer.  
Combustion and HPLC analysis confirmed that the target compounds possessed purities ≥ 95%.  
 
7-(4-Amino-2,2,6,6-tetramethyl-1-piperidinyloxy)bicyclo-[3.3.1]nonane-3-carboxylic acid 
(OZH04).  Step 1. To a solution of adamantane-2-spiro-3'-1',2',4',9',12'-
pentaoxadispiro[4.2.4.2]tetradecane (1)1 (0.70 g, 2.17 mmol), 4-((tert-butoxycarbonyl)amino)-
2,2,6,6-tetramethylpiperidinyl-1-oxyl (2) (0.70 g, 2.58 mmol) in CH2Cl2 (30 mL) and CH3CN (30 mL) 
was added Fe(OAc)2 (0.70 g, 4.03 mmol). The resulting mixture was stirred under Ar and 35 °C for 
24 h before being quenched with water (50 mL). After separation of the organic layer, the aqueous 
layer was extracted with CH2Cl2 (2 x 30 mL). The combined extracts were washed with brine (2 x 
30 mL), dried over MgSO4 and filtered and concentrated. The residue was purified by flash 
chromatography (silica gel, 10-50% ether in hexane) to afford 7-(4-((tert-butoxycarbonyl)amino)-
2,2,6,6-tetramethyl-1-piperidinyloxy)bicyclo-[3.3.1]nonane-3-carboxylic acid (3) (mixture of 
rotamers) as a colorless solid (0.25 g, 26%). 1H NMR (CDCl3) δ 1.17 (s, 6H), 1.20 (s, 6H), 1.44 (s, 9H), 
1.00-1.52 (m, 7H), 1.56 (d, J = 14 Hz, 1H), 1.66-1.82 (m, 2H), 2.00-2.28 (m, 6H), 2.40-2.54 (m, 1H), 
3.55-3.68 (m, 0.4H), 3.72-3.86 (m, 0.6H), 3.95-4.08 (m, 1H), 4.30-4.40 (m, 0.6H), 6.48 (m, 0.4H); 13C 
NMR (CDCl3) δ 20.77, 20.99, 25.93, 28.39, 29.21, 29.46, 33.70, 34.15, 35.16, 35.58, 39.70, 39.96) 
42.16, 43.16, 45.87, 59.67, 60.25, 75.64, 79.24, 80.36) 155.23, 157.51, 180.79, 181.06.  Step 2.  A 
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mixture of 3 (0.15 g, 0.34 mmol) and 6 N HCl (0.50 mL) in THF (20 mL) was stirred at rt overnight. 
After removal of solvent, the residue was washed with CH2Cl2 to afford OZH04 dihydrochloride 
monohydrate as a white solid (0.12 g, 92%).   1H NMR (D2O) δ 1.19 (d, J = 13 Hz, 1H), 1.41 (t, J = 
12.5 Hz, 2H), 1.49 (s, 6H), 1.57 (s, 6H), 1.50-1.70 (m, 3H), 2.06 (t, J = 13 Hz, 2H), 2.14-2.38 (m, 4H), 
2.38-2.44 (m, 4H), 2.55-2.66 (m, 1H), 3.82-3.95 (m, 1H), 4.55-4.68 (m 1H); 13C NMR (D2O) δ 20.22, 
26.26, 27.58, 28.78, 28.85, 35.01, 38.27, 40.37, 41.51, 69.63, 83.83, 181.63.  Anal. Calcd for 
C19H36Cl2N2O3  H2O: C, 53.14; H, 8.92; N, 6.52. Found: C, 52.97; H, 8.63; N, 6.41. 
 
N-(1-Methoxy-2,2,6,6-tetramethylpiperidin-4-yl)acetamide (OZH05).  To a solution of 4-acetamido-
2,2,6,6-tetramethylpiperidinyl-1-oxyl (1.0 g, 4.33 mmol) in acetone (20 mL) was added CuCl (20 
mg, 0.12 mmol) followed by 50% H2O2 (1.0 mL). The reaction mixture was stirred at rt overnight 
and then concentrated. The residue was diluted with CH2Cl2 (20 mL), washed with brine (2 x 10 
mL), dried over MgSO4 and concentrated to afford OZH05 as a white solid (0.68 g, 64%).   1H NMR 
(CDCl3) δ 1.18 (s, 6H), 1.19 (s, 6H), 1.30 (t, J = 12 Hz, 2H), 1.78 (d, J = 11 Hz, 2H), 1.94 (s, 3H), 3.60 
(s, 3H), 4.06-4.18 (m, 1H), 5.08 (brs, 1H); 13C NMR (CDCl3) δ 20.45, 23.50, 32.86, 41.01, 45.63, 59.82, 
65.36, 169.42. Anal. Calcd for C12H24N2O2: C, 63.12; H, 10.59; N, 12.27. Found: C, 62.93; H, 10.37; N, 
11.93. 
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SI Figure 1:  
Immunofluorescence co-localisation studies with P. falciparum rings (top row) and schizonts 
(bottom row) that were treated with 10 µg/mL OZ277 for 2 h. The blood smears were fixed with 
prechilled methanol (-20 °C; 100%) and blocked with 1% BSA in PBS for 1 h. Scale bar 2 µm. The 
primary antibodies used were directly labelled OZH04-2/2 (Alexa 488, green signal) and GAPDH 
(Alexa 594, red signal).  The left column shows parasites with OZH04-2/2 with an exposure of 2 s. 
The next column shows GAPDH with an exposure of 2 s, followed by DAPI staining (blue signal) 
with an exposure of 0.025 s and a scale bar of 2 µm, and then a merge of OZH04-2/2, GAPDH and 
DAPI. The last image is a merge of OZH04-2/2, GAPDH, DAPI and the reference image (exposure 
0.1 s). Scale bar 2 µm. 
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SI Figure 2:  
a) Western blot with mixed P. falciparum cultures. Cultures were treated with 10,000, 1,000, 100, 
10, 1 and 0.1 ng/mL OZ277 or a DMSO control for 2 h. Under these experimental condition, a 
concentration of 100 ng/mL corresponds to ~1x IC99. Antibody OZH04-2/2 and a film exposure 
time of 1 s were used. 
b) Longer film exposure (1 minute) of same blot. 
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SI Figure 3: 
 a) Western blot with uninfected erythrocytes (RBCs), which were treated with 10 µg/mL OZ277, 
OZ439, CarbaOZ277 or a DMSO control for 2 h. Positive control samples from infected erythrocytes 
(SL, saponin lysate) are loaded next to the left and middle protein marker. Antibody OZH04-2/2 
and a film exposure time of 1 s were used. b) Coomassie stained gel. All samples were normalized 
for their protein content.  
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SI Figure 4:  
a) Western blot of Babesia divergens cultures that were treated with 10 µg/mL OZ277, OZ439, 
CarbaOZ277 or a DMSO control for 2 h. Streptolysin O was used for lysis as previously described.2 
A positive control sample from P. falciparum infected erythrocytes (saponin lysates) is shown next 
to the DMSO control sample. Antibody OZH04-2/2 and a film exposure time of 1 min were used. 
b) Coomassie stained gel. All samples were normalized for their protein content.  
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Abstract 
Background 
Recently published data suggest that artemisinin derivatives and synthetic peroxides, such as the 
ozonides OZ277 and OZ439, have a similar mode of action. Here the cross-resistance of OZ277 and 
OZ439 and four additional next-generation ozonides was probed against the artemisinin-resistant 
clinical isolate Plasmodium falciparum Cam3.I, which carries the K13-propeller mutation R539T 
(Cam3.IR539T). 
Methods 
The previously described in vitro ring-stage survival assay (RSA0-3h) was employed and a simplified 
variation of the original protocol was developed. 
Results 
At the pharmacologically relevant concentration of 700 nM, all six ozonides were highly effective 
against the dihydroartemisinin-resistant P. falciparum Cam3.IR539T parasites, showing a per cent 
survival ranging from <0.01 to 1.83%. A simplified version of the original RSA0-3h method was 
developed and gave similar results, thus providing a practical drug discovery tool for further 
optimization of next-generation anti-malarial peroxides. 
Conclusion 
The absence of in vitro cross-resistance against the artemisinin-resistant clinical isolate Cam3.IR539T 
suggests that ozonides could be effective against artemisinin-resistant P. falciparum. How this will 
translate to the human situation in clinical settings remains to be investigated. 
Keywords Ring-stage survival assay, Artemisinin, Ozonide, Plasmodium falciparum, Cam3.IR539T, 
Drug resistance 
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Background 
Malaria is one of the most important tropical diseases resulting in 214 million new cases and an 
estimated 438,000 malaria deaths worldwide in 2015 [1]. The discovery of artemisinin in the 1970s 
was an important step forward in anti-malarial drug therapy and was recognized with the Nobel 
Prize in Physiology or Medicine in 2015 [2,3]. Artemisinin and its semi-synthetic derivatives, such 
as dihydroartemisinin (DHA) (Fig. 1), artesunate and artemether, contain a unique sesquiterpene 
lactone peroxide (1,2,4-trioxane) structure and artemisinin-based combination therapy (ACT) 
represents the current first-line treatment of uncomplicated Plasmodium falciparum malaria [4,5,6]. 
Since the starting material artemisinin is a natural product, its production is limited to the 
availability of the plant [7,4], although several total syntheses of artemisinin have been described 
[8]. In 2004, Vennerstrom et al. reported the discovery of a completely synthetic peroxide anti-
malarial containing a 1,2,4-trioxolane (ozonide) pharmacophore named OZ277 (arterolane) (Fig. 1) 
with anti-malarial activity comparable to the artemisinin derivatives [9,10]. In combination with 
piperaquine, arterolane was registered for anti-malarial combination therapy in India in 2011 
[11,12,13,14]. The next-generation ozonide, OZ439 (artefenomel) (Fig. 1), exhibits an increased 
pharmacokinetic half-life and good safety profile and is now being tested in phase IIb clinical trials 
[12,14,15,16,17]. The iron-dependent alkylation hypothesis is one of the proposed modes of action 
of artemisinin and synthetic peroxides [18,19,20,21] where the peroxide is thought to be activated 
by the reductive cleavage in the presence of ferrous haem (or free Fe(II) derived from haem) released 
as a by-product of hemoglobin digestion in the food vacuole [20,22,23,24, 25,26,27]. Thereby 
carbon-centred radicals are generated, which then alkylate haem and parasite proteins 
[28,29,30,31,32,33]. The interaction of the artemisinin derivatives or ozonides with parasite targets 
is irreversible [31,34]. Although the semi-synthetic artemisinins are highly effective, prolonged 
parasite clearance times were first reported along the Thai–Cambodian border in 2006, suggesting 
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an emerging artemisinin resistance phenotype [35]. Today, delayed parasite clearance following 
treatment with artemisinin derivatives has been observed across Southeast Asia [36,37,38,39,40,41]. 
It was found that mutations in the Kelch 13 propeller domain are associated with ring-stage parasites 
entering a quiescent state with delayed parasite clearance after exposure to artemisinins 
[41,42,43,44,45]. When 50% inhibitory concentrations (IC50) were measured using conventional 
methods such as the [3H] hypoxanthine incorporation assay [46], no difference was observed 
between artemisinin-resistant and -susceptible strains after treatment with artemisinin or its 
derivatives [47,48,49,50]. In an effort to correlate the delayed parasite clearance observed in vivo 
with in vitro parasite survival, Witkowski et al.  [48,49] developed a ring-stage survival assay (RSA0-
3h) that exploited the differences in susceptibility observed between wild-type and K13 mutants at 
the early ring stage of the asexual blood cycle following a short pulse of artemisinin treatment. In 
the RSA0-3h, synchronized young ring stage parasites (0-3 hrs old) are exposed to drugs for six hours, 
and then cultured in drug free culture medium for 66 hours before relative growth is determined 
by microscopic analysis [48,49]. Since the structural analogies between artemisinins and ozonides 
(Fig. 1) suggest that they share similar modes of action, and thus some level of cross resistance 
[9,10,51,52], the per cent survival of an artemisinin-resistant clinical isolate (Cam3.IR539T) treated 
with DHA, OZ277, OZ439, and four additional next-generation ozonides (Fig. 1) using the RSA0-3h 
as described by Witkowski et al. [48,49] was evaluated. Additionally, a sub-set of these compounds 
was tested in the RSA0-3h described by Xie et al. [53] that also uses tightly synchronized ring-stage 
cultures, but allows the assay to be performed routinely within a convenient time-frame. 
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Methods 
Parasite cultivation 
The artemisinin-resistant P. falciparum isolate Cam3.IR539T from Battambang, Cambodia was 
obtained from BEI Resources [54] with the accession number MRA-1240. The drug-sensitive P. 
falciparum strain NF54 (airport strain from The Netherlands) was provided by F. Hoffmann-La 
Roche Ltd. Parasites were cultivated in standard cultivation medium, consisting of hypoxanthine 
(50 mg/l), RPMI (10.44 g/l) supplemented with HEPES (5.94 g/l), albumax (5 g/l), sodium 
bicarbonate (2.1 g/l) and neomycin (100 mg/l) [55]. 
Ring-stage survival assays (RSA0-3h) 
Ring-stage survival assays (RSA0-3h) were carried out essentially as previously described by 
Witkowski et al. [48], but with a few modifications in the drug-washing procedure to ensure that 
no residual peroxide was present during the 66-hour post-treatment period [56]. Briefly, zero to 
three hours post-invasion ring stages were adjusted to 1% parasitaemia and 2.5% haematocrit by 
adding uninfected erythrocytes, transferred in a total volume of 1 mL into 48-well plates and 
exposed for six hours to a range of concentrations (700, 350, 175, 88, and 49 nM) of DHA or one of 
the six ozonides tested in this study. The synthesis of the four next-generation ozonides, OZ493, 
OZ609, OZ655 and OZ657, will be reported in due course by the laboratory of Prof. Jonathan 
Vennerstrom (manuscript with ID jm-2016-01586n in the Journal of Medicinal Chemistry is currently 
in press). After six hours, cultures were transferred to 15 mL conical tubes, centrifuged at 1,400 rpm 
(400 g) for 2 min and carefully washed two times with 12 mL of culture medium. The complete 
removal of compound after washing was verified by incubating the supernatant recovered after the 
last washing step with fresh cultures of NF54 parasites, ensuring that no growth inhibition was 
detected. After washing, blood pellets were resuspended in complete drug-free culture medium, 
transferred into new wells and cultured for 66 hours under standard conditions. 
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Thin blood smears were prepared, methanol-fixed and stained with 10% Giemsa. Per cent survival 
was assessed using light microscopy, counting the number of parasitized cells in ≥10,000 red blood 
cells (RBCs) and comparing survival to that of the drug-free dimethylsulfoxid incubation. 
Microscopy analysis was performed independently by two microscopists, one having more than 15 years 
of work experience. 
Alternative parasite synchronization method 
Parasites were synchronized according to Xie et al. [53] with 5% d-sorbitol. After 30 and 43 hours, 
parasites were synchronized a second and third time, respectively, resulting in zero to one-hour old 
ring-stage parasites. The RSA0-3h was initiated two hours later. 
Standard [3H] hypoxanthine incorporation assay 
The in vitro anti-malarial activity was measured using the [3H]-hypoxanthine incorporation assay 
[55]. Results were expressed as the concentration resulting in 50% inhibition (IC50). 
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Results  
The per cent survival of parasites exposed to a concentration range of DHA and six different 
ozonides (Fig. 1) was determined using the artemisinin-resistant P. falciparum Cambodian isolate 
Cam3.IR539T. As expected, DHA exposure gave a high survival rate ranging from 74 to 33% at 
concentrations of 49 and 700 nM, respectively (Fig. 2), which is comparable to the observed survival 
value of 40% at 700 nM published previously [44]. In contrast, when tested at 700 nM, the two 
ozonides OZ277 and OZ439 showed an approximate 18- to 45-fold increase in potency compared 
with DHA (Fig. 2). Full and equal potency was observed when DHA, OZ277 and OZ439 were tested 
in parallel in the RSA0-3h using the artemisinin-sensitive strain NF54 (Supplementary Table S1). At 
the lowest concentration (49 nM), OZ277 had poor activity, showing a similar per cent survival to 
that of DHA, whereas OZ439 was still about five-fold more potent. A possible explanation for 
OZ439 being more potent than OZ277 could be related to its improved stability in blood as 
previously described [15]. In those studies, OZ277 or OZ439 were incubated at 37°C in P. 
falciparum-infected human blood. After 2 hours more than 90% of OZ277 was degraded, whereas 
OZ439 was found to be about 10-20x more stable. A similar and more recent study found similar 
differences in stability for OZ277 and OZ439 [56]. The same compounds were also tested in a more 
convenient variation of the standard RSA0-3h that uses synchronized ring-stage cultures that can be 
easily produced during normal working hours [53]. As shown in Table 1, this alternative 
synchronization method gave results that were comparable to those obtained using the standard 
RSA0-3h. 
To investigate further the level of cross-resistance between DHA and the ozonides, four additional 
next-generation ozonides (OZ493, OZ609, OZ655, OZ657) (Fig. 1) were tested against the 
Cam3.IR539T parasites. While all six ozonides had a similar IC50 value using a conventional 72-hour 
[3H] hypoxanthine incorporation assay (Supplementary Table S2), the RSA0-3h showed that OZ493, 
61 | P a g e  
 
OZ609 and OZ655 were highly potent and completely inhibited the growth of the artemisinin-
resistant isolate at the two highest concentrations tested (Fig. 2). At the lowest concentration, 
potency was comparable to that for OZ439. The overall potency of OZ657 was comparable to that 
of OZ277. 
The RSA0-3h was recently developed to provide an in vitro correlate of the longer in vivo parasite 
clearance times observed after artemisinin treatment in Southeast Asia, which is widely interpreted 
as a sign of potential artemisinin resistance [57,58]. Provided that the RSA0-3h does indeed predict 
the potency of compounds against artemisinin-resistant parasites in malaria patients, the here 
described data suggest that all of the tested ozonides are highly potent against isolates such as P. 
falciparum Cam3.IR539T. These data are in line with the recent clinical observation that the parasite 
clearance rate following OZ439 treatment is not significantly affected by resistance-associated 
mutations in the Kelch 13 propeller region [17] and the recent data published by Siriwardana et al. 
[59], which showed no reduced susceptibility of OZ439 in a different delayed clearance phenotype 
parasite (Cam3.II) in vitro. 
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Conclusion 
In the traditional RSA0-3h, as well as a more convenient variation of the original method, all of the 
tested ozonides, were highly potent against the artemisinin-resistant isolate P. falciparum 
Cam3.IR539T in contrast to results for DHA. These data indicate that artemisinin-resistant P. 
falciparum infections could be successfully treated with ozonide anti-malarial drugs. 
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OZ277: arterolane; OZ439: artefenomel; DHA: Dihydroartemisinin; ACT: Artemisinin combination 
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Fig. 1  Chemical structures of dihydroartemisinin (DHA) and the six ozonides investigated  
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Fig. 2  Mean per cent survival ± standard error (SE) of Plasmodium falciparum isolate Cam3.IR539T parasites after a 6-hour 
exposure to a range of concentrations of dihydroartemisinin (DHA) or six different ozonides  
Three biological replicates were performed per compound. 
 
 
  
49 nM 88 nM 175 nM 350 nM 700 nM
DHA 73.50 60.03 47.94 37.68 33.02
OZ277 53.80 16.87 4.65 2.20 1.83
OZ439 13.70 0.93 0.73 0.73 0.73
OZ493 3.19 0.00 0.53 0.00 0.00
OZ609 1.29 0.17 0.12 0.00 0.00
OZ655 0.76 0.00 0.00 0.00 0.00
OZ657 59.10 22.93 2.33 0.00 0.00
0
10
20
30
40
50
60
70
80
90
100
P
e
rc
e
n
t 
su
rv
iv
al
74 | P a g e  
 
Table 1 Mean per cent survival (individual values in brackets)  of Cam3.IR539T isolate after 6 hours exposure to a range of 
concentrations of DHA, OZ439 or OZ277 using the synchronization protocol from Xie et al. [53]. 
Two biological replicates were performed per compound. 
 
Compounds RSA values (per cent survival) at different concentrations 
 175 nM 350 nM 700 nM 
DHA 46 (49,43) 42 (45,39) 37 (39,35) 
OZ277 4.0 (4.4,3.6) 2.3 (1.9,2.7) 1.4 (1.7,1.1) 
OZ439 <0.01 (<0.01,<0.01) <0.01 (<0.01,<0.01) <0.01 (<0.01,<0.01) 
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Supplementary Table S1 Mean per cent survival (individual values in brackets) of NF54 after 6 hours exposure to 500 nM 
of DHA, OZ439 or OZ277 using the synchronization protocol from Straimer et al. [44.] 
Two biological replicates were performed per compound. 
 
Compounds Per cent survival 
DHA <0.01 (<0.01,<0.01) 
OZ277 <0.01 (<0.01,<0.01) 
OZ439 <0.01 (<0.01,<0.01) 
 
 
Supplementary Table S2  Mean in vitro IC50 values (single values in brackets) for Plasmodium falciparum isolate Cam3.IR539T 
and NF54 in the 72-hour [3H] hypoxanthine assay 
Two biological replicates were performed per compound. 
 
Compounds IC50 (nM) 
Cam3.IR539T 
IC50 (nM) 
NF54 
DHA 1.5 (1.7,1.3) 2.6 (2.4,2.8) 
OZ277 1.8 (1.8,1.8) 1.7 (1.7,1.8) 
OZ439 4.6 (4.6,4.6) 4.2 (4.6,3.9) 
OZ493 3.6 (3.6,3.7) 3.8 (4.5,3.1) 
OZ609 1.8 (1.8,1.8) 1.3 (1.4,1.2) 
OZ655 2.8 (2.7,2.8) 2.5 (2.3,2.7) 
OZ657 2.9 (2.9,2.9) 2.3 (2.3,2.3) 
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Abstract 
Antimalarial peroxides such as the phytochemical artemisinin or the synthetic artefenomel are 
prodrugs that need to be activated by reductive cleavage of the peroxide bond. This happens inside 
the malaria parasite, presumably in the food vacuole with ferrous heme as the electron donor. The 
generated radicals will then alkylate heme itself and proteins. Here we determine the alkylation 
signatures of artemisinin and synthetic ozonides by chemical proteomics in Plasmodium falciparum 
using alkyne probes that allow to identify the target proteins by click chemistry and affinity 
purification. Two forms of controls are included: the non-clickable parent peroxides, as well as non-
peroxidic derivatives of the alkyne probes. These permitted to stringently determine the target space 
of the peroxides, identifying a total of 18 proteins for artemisinin and 41 for the synthetic ozonides, 
with an intersect of 14. We further compare the alkylation signatures of the antimalarial peroxides 
to each other and to previously published datasets. 
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Introduction 
Malaria remains one of the most prevalent infectious diseases worldwide, with an estimated death 
toll of 429,000 in 2015 (WHO Report 2016). The most lethal form of malaria, malaria tropica, is 
caused by Plasmodium falciparum. The current first-line treatments for malaria tropica are the 
artemisinin-based combination therapies, ACTs (White, 2008), such as artemether-lumefantrine 
(Coartem) or dihydroartemisinin-piperaquine (Artekin; Anthony et al., 2012). Artemisinin, 
discovered in 1971 by Youyou Tu (Tu, 2011), is a sesquiterpene lactone with an endoperoxide bridge 
(Figure 1). It is of highest activity and specificity against malaria parasites. However, as a natural 
product artemisinin has two limitations: its production is laborious and constrained by the 
availability of the plant Artemisia annua, and its pharmacological properties are difficult to improve 
(Avery et al. 1992, Klayman et al. 1985, Kumar et al 2005). Thus, synthetic antimalarial peroxides 
are a promising alternative for future antimalarials (Vennerstrom et al., 2004; O`Neill et al., 2017). 
Vennerstrom and co-workers concentrated on the synthesis of adamantane-based 1,2,4-trioxolanes 
(Figure 1), herein called ozonides, and presented a first drug candidate, OZ277 or arterolane maleate 
in 2004 (Vennerstrom et al., 2004; Tang et al., 2004). In spite of its suboptimal stability in P. 
falciparum-infected blood, arterolane maleate was subsequently registered for antimalarial therapy 
in India in combination with piperaquine phosphate (Synriam®; Mäser et al., 2012; Anthony et al., 
2012; Patil et al., 2014; Wells et al., 2015). A next generation ozonide with improved 
pharmacokinetic properties, OZ439 or artefenomel, is presently being tested in phase IIb clinical 
trials in combination with ferroquine (Charman et al., 2011; Moehrle et al., 2013; Wells et al., 2015, 
Phyo et al., 2016 and Blasco et al., 2017). 
Artemisinins and ozonides are thought to possess similar modes of action since for both classes, the 
endoperoxide bridge was found to be necessary for antimalarial activity (Klayman 1985; Kaiser et 
al. 2007). One of the proposed modes of actions is therefore the iron-dependent artemisinin 
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alkylation hypothesis (Kaiser et al., 2007; Creek et al., 2008; Meunier et al., 2010), which suggests 
that ferrous heme, or FeII derived from heme, is released as a product of hemoglobin digestion in 
the parasite's food vacuole and leads to a reductive cleavage of the peroxide bond (Klonis et al., 2011; 
Robert et al., 2013; Klonis e al., 2013; Hartwig et al., 2009). This generates highly reactive radicals 
that alkylate intracellular targets such as proteins and heme itself (Asawamahasaksa et al., 1994; 
Meshnick, 2002; Tilley et al., 2011). The alkylation hypothesis is supported by the findings that the 
digestive vacuole is an important initial site for antimalarial peroxide activity (Crespo et al.; 2008; 
Uhlemann et al., 2007), and that artemisinin and OZ277 are inactive against pathogens that do not 
degrade hemoglobin (Kaiser et al., 2007). The formation of carbon-centered radicals was found to 
be critical for the activity of antimalarial peroxides (Tang et al., 2005; Hartwig et al., 2011, Fügi et 
al., 2010) and the activities of artemisinin as well as ozonides do not derive from reversible 
interactions with parasite targets (Fügi et al., 2010; Abiodun et al., 2013).  
The elucidation of the mode of action and identification of the intracellular targets of the 
antimalarial peroxides has become all the more pressing after the emergence of artemisinin-resistant 
P. falciparum isolates in South-East Asia (Noedl et al., 2008; Dondorp et al., 2009), and recently also 
in Africa (Lu et al., 2017), whose mechanism of resistance is not fully understood either (Blasco et 
al., 2017). Alkyne-tagged artemisinins and 1,2,4-trioxolanes have been used as chemical probes for 
activity-based profiling of the peroxide target signatures in P. falciparum (Wang et al., 2015; Ismail 
et al., 2016a; Ismail et al., 2016b), and the alkylation signature of a clickable 1,2,4-trioxolane was 
found to be similar to that of artemisinin (Ismail et al., 2016b). Here we further sharpen this 
approach, assessing the alkylation signatures of artemisinin and ozonides in parallel, and including 
control molecules that allow to focus on those drug-target interactions that depend on the presence 
of a peroxide bond.   
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Results 
Design and synthesis of alkynes as chemical probes 
If the peroxides are indeed activated by reductive cleavage and subsequently alkylate proteins, then 
the covalent interaction between drug and target will facilitate the identification of the latter. We 
designed alkyne derivatives of artemisinin and of an archetypal ozonide, OZ03, as chemical probes 
that can be linked by azide-alkyne Huisgen cycloaddition (click-chemistry; Kolb et al., 2001) to 
biotin or other markers (Figure 1). In addition to the parent compounds, which allow to discriminate 
false positive hits, we included a second type of control molecules that possessed the alkyne group 
but lacked the peroxide bridge: the deoxy form of the artemisinin alkyne, deoxyAA2, and the carba 
form of OZ727, carbaOZ727 (Figure 1). These allow to discriminate hits that may actually be bound 
by the probes, but not by means of peroxide reactivity. 
 
Figure 1. Chemical structures of the parent molecules artemisinin and OZ03 plus the newly synthesized alkyne 
derivatives as chemical probes.  
 
Bioactivity of the chemical probes 
The 50% inhibitory concentrations (IC50) of the newly synthesized alkynes against intraerythrocytic 
P. falciparum in culture were determined using the [3H]-hypoxanthine incorporation assay 
(Desjardins et al., 1979). The alkynes AA2, OZ726 and OZ727 were highly active against P. 
falciparum NF54 parasites, whereas the nonperoxidic analogues carbaOZ277, carbaOZ727 and 
deoxyAA2 were at least 1,000-fold less active (Table 1). Thus, as expected, the antiplasmodial 
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activity was dependent on the presence of the peroxide bridge, while the chosen alkyne 
modifications did not compromise the antiplasmodial activity of the molecules. In particular, it was 
interesting to note that the ozonides appeared to permit modification of the adamantane moiety. 
 
 
 
Peroxide? Alkyne? IC50 [ng/ml] 
AA2 Yes Yes 2.44 
Artemisinin Yes No 2.28 
DeoxyAA2 No Yes >10,000 
OZ439 Yes No 2.03 
OZ277 Yes No 0.91 
CarbaOZ277 No No 4,900 
OZ03 Yes No 2.36 
OZ726 Yes Yes 0.74 
OZ727 Yes Yes 0.98 
CarbaOZ727 No Yes >10,000 
 
Table 1. Mean IC50 values of the parent molecules and the newly synthesized alkynes against 
P. falciparum NF54. All assays were performed in three biological replicates. 
 
Protein alkylation by the chemical probes 
A series of pilot experiments was carried out to optimize the incubation parameters (Figure S1) and 
the reaction conditions for click chemistry. In brief (see Material and Methods for details), P. 
falciparum cultures were incubated for 4 h with a chemical probe, followed by harvesting and lysis 
of the parasites. The protein extracts were then treated with biotin-azide under copper to catalyze 
the cycloaddition with the alkyne. After acetone precipitation, the samples were run on 
polyacrylamide gels for Western blotting, using streptavidin-coupled horseradish peroxidase to 
detect the alkylated proteins. 
Parasite cultures treated with 1 µg/ml AA2, OZ726 or OZ727 produced clear signals with 
reproducible banding patterns, whereas neither the non-clickable parent compounds nor the 
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nonperoxidic alkynes gave a signal on the Western blot (Figure 2A). The signal of the alkyne OZ726 
was outcompeted by increasing ratios of the parent compound OZ03 (Figure 2B), indicating that the 
parental ozonide and the alkyne derivative have the same binding sites and that binding is saturable. 
These results confirmed that the peroxides covalently bind to proteins, as was known from previous 
studies (Meshnick et al., 1993), and that they possess specific alkylation signatures rather than 
binding unspecifically to all the P. falciparum proteins (Asawamahasakda et al., 1994; Fügi et al., 
2010; Abiodun et al., 2013). In order to identify these alkylation signatures by mass spectrometry, 
we tested whether the click chemistry also works for precipitation of the bound proteins with 
neutravidin-coupled agarose beads. This was indeed the case: protein bands were detected by 
Western blot in P. falciparum cultures treated with 100 ng/ml AA2, whereas no bands were 
observed in parasite cultures treated with 0.1% DMSO. Negative controls such as the neutravidin 
beads alone or uninfected erythrocytes without drug gave no signal (Figure 2C).  
 
Figure 2. Western blot experiments with P. falciparum cultures treated with (A) 1 µg/ml OZ726, OZ727, AA2, 
OZ03, carbaOZ727, deoxyAA2 or artemisinin for 4 h, protein extracts prepared with 1.2% SDS in PBS, exposure 
time 1 min, and (B) competing concentrations of OZ726 and the non-clickable parent OZ03 for 2 h, extracts 
prepared with Ripa-Lysis buffer, exposure time 10 s. (C) shows a precipitation experiment with cultures treated 
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with 100 ng/ml AA2 in 0.1% DMSO for 4 h and different negative controls. Protein extracts were prepared 
with 1.2% SDS in PBS and precipitated with neutravidin agarose resin; exposure time 1 min. 
 
Mass spectrometry-based proteomics to identify alkylated proteins 
The proteomics experiments were performed at an about 30x higher parasitemia (10%) compared 
to the hypoxanthine incorporation assays (0.3%). From previous work it is known that a 30x higher 
parasitemia results in a 30x higher inhibitory concentration (Jourdan et al., 2015). As a consequence, 
in the here described studies we treated P. falciparum NF54 cultures of 7% to 12% parasitemia with 
100ng/ml (corresponding to about an IC99) as well as 1000ng/ml artemisinin, AA2, deoxyAA2, OZ03, 
OZ726, OZ727, carbaOZ727 or DMSO only, each in biological triplicates. The lysed samples were 
subjected to click-chemistry with biotin-azide as above, incubated with neutravidin agarose beads, 
and washed extensively (see Figures S2 and S3 for optimization of the washing conditions). The 
bound proteins were eluted, digested with trypsin, and processed for mass spectrometry as described 
in Material and Methods. The proteins were identified by their fingerprints of trypsin fragments as 
compared to the predicted peptides of the proteome of P. falciparum NF54 (Uniprot ID 
UP000030673).   
Overall only 59 different proteins were significantly (>1.8 fold, p<0.05) enriched in any one of the 
probe-treated cultures vs. the DMSO-treated control, indicating again that the peroxides have 
specific alkylation signatures. The results are summarized in Tables S1 and S2. All the proteins that 
were also obtained with the unmodified parent molecules, 1 (PFNF54_01079, dihydrofolate 
reductase-thymidylate synthase) for artemisinin and 10 for OZ03 (Table S1), were removed from 
the list of hits. Next, we removed the hits that were also obtained with the nonperoxidic alkyne 
probes, 6 for deoxyAA2 but 0 for carbaOZ727 (Table S1). A potentially interesting hit among the 
proteins fished with deoxyAA2 was 1-cys peroxiredoxin (PFNF54_02028), since another P. 
falciparum peroxiredoxin, PfAOP, had been implicated in artemisinin susceptibility (Djuika et al., 
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2017). The removal of all the hits that turned up in any of the control samples yielded a final list of 
45 P. falciparum proteins that were bound by the chemical probes by means of peroxide activity 
(Table 2). 
 
Alkylation signatures of artemisinin and ozonides 
We used the 100 ng/ml samples to compare the alkylation signatures of artemisinin and the two 
ozonides. A total of 25 different P. falciparum proteins was alkylated by either AA2, OZ726 or 
OZ727 (Table 2). Unsurprisingly, the largest degree of overlap was between the identified target 
spaces of OZ726 and OZ727 (Figure 3A). There was also a clear overlap between the identified 
targets of AA2 with those of OZ726, and to a lesser extent with those of OZ727 (Figure 3A). Only 
one protein was identified with all three peroxides: PFNF54_01699, which corresponds to 
PlasmoDB entry PF3D7_0706500. However, this protein is not linked to any publication and does 
not contain any known domains (according to PlasmoDB). A blastp search with PF3D7_0706500 
revealed significant similarity to proteins annotated as erythrocyte membrane proteins in P. 
coatneyi and P. yoelii, as well as a PfEMP3-like protein in P. berghei. The latter contains an RNA 
recognition motif (RRM) that was also found by the NCBI algorithm during the blastp search. 
 
 
 
 
 
 
Figure 3. Venn diagrams of (A) all the hits obtained after treatment with 100 ng/ml artemisinin alkyne, OZ726 or 
OZ727; and (B) and of all the hits identified with an alkyne derivative of artemisinin in the present study compared to 
three published datasets (Wang et al., 2015; Ismail et al., 2016a and b). 
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The samples incubated with 1000 ng/ml of the chemical probes, though arguably a less physiological 
concentration than 100 ng/ml, also yielded a number of interesting hits, and they had a stronger 
overlap between the artemisinine-alkyne and ozonide-alkyne samples. Nine of the 11 proteins 
identified with AA2 were also present in the target space of OZ726. However, OZ726 alkylated an 
additional 16 proteins that were not identified in any of the AA2 1000 ng/ml experiments (Table 2). 
Thioredoxin peroxidase 1 and a thioredoxin-related protein were identified as alkylation targets of 
both artemisinin and synthetic peroxides (Table 2). Proteins of interest that were identified with 
ozonide alkynes but not with artemisinin alkyne were subunits of the V-type ATPase, multidrug 
resistant protein 1, the proteasome subunit beta type-6, aminopeptidase P and plasmepsin III (Table 
2).  
 
Comparison to published datasets 
The obtained results (Table 2) were compared with other studies that had also used alkyne 
derivatives of antimalarial peroxides, followed by click chemistry and mass spectrometry-based 
proteomics, to identify potential targets (Wang et al., 2015; Ismail et al., 2016a and 2016b). Table 3 
lists all the common hits with these studies, Figure 3B focuses on the intersects between the hits 
obtained with artemisinin-alkynes. The overlap of our results with those of Wang et al. was larger 
than with those of Ismail et al. Using AA2 (Figure 1), we have identified a total of 18 hits (Figure 
3B, Table 2), of which 8 were also identified in the 124 hits by Wang et al (p, assuming a protein 
space of 3000), while there was only 1 common protein between our hits and the 58 hits obtained 
by Ismail et al. (Figure 3B). The negative controls were DMSO in Wang et al, and DMSO and 
nonperoxidic-alkynes in Ismail 2016a.  
86 | P a g e  
 
Discussion 
The present study is in agreement with earlier work (Asawamahaska et al., 1994; Jourdan et al., 
2015; Ismail et al 2016a and b; Wang et al., 2015) to support the notion that antimalarial peroxides 
covalently bind target molecules in P. falciparum after reductive bioactivation of the peroxide 
bridge. Heme itself is among these targets (Robert et al., 2005; Creek et al., 2008), and we cannot 
exclude further non-proteinaceous structures to be alkylated as well.  Here we focus on the protein 
targets of artemisinin and synthetic ozonides, since these are straightforward to identify by mass 
spectrometry based on their fingerprints after digestion with trypsin. The same approach, using 
alkyne derivatives as chemical probes, had been taken by two other labs (Wang et al., 2015; Ismail 
et al., 2016a and b). While there was a clear overlap between the target spaces identified herein and 
those by Wang et al. (2015), there is less consistency with the data from Ismail et al. (2016 a and b; 
Table 3). This might be because the two former sets of experiments were performed with 
unsynchronized cultures of the P. falciparum erythrocytic cycle, whereas the latter concentrated 
on trophozoites. Furthermore, the present study incorporated additional controls in the form of the 
non-alkyne parent molecules artemisinin and OZ03, plus the aperoxidic, inactive but clickable 
molecules deoxyAA2 and carbaOZ727 (Figure 1). These turned out to be helpful to scrutinize the 
obtained hits. Dihydrofolate reductase-thymidylate synthase (DHFR-TS, PF3D7_0417200), for 
example, had been identified as a candidate target of artemisinin (Ismail et al., 2016a) and was also 
isolated here with all the clickable peroxides, AA2, OZ726 and OZ727 (Table S1). However, as 
DHFR-TS was also isolated with the non-clickable controls artemisinin and OZ03, and with the 
non-peroxidic control deoxyAA2 (Table S1), it was removed from the list of alkylation targets (Table 
1). The remaining intersect of the protein sets identified by the different proteomics studies (Table 
2) present a robust set of candidate alkylation targets of antimalarial peroxides. 
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It was also interesting to compare our results to the study by Asawamahaska et al., who had used 
radiolabeled dihydroartemisinin as a probe to identify four major P. falciparum protein bands of 25 
kDa, 50 kDa, 65 kDa and >200 kDa, plus two minor bands of 32 kDa and 42 kDa as the alkylation 
signature (Asawamahasakda et al., 1994). This resembled the pattern observed by Western blot with 
artemisinin alkyne (Figure 2C), with protein bands at ~25 kDa, ~50 kDa, ~68 kDa, ~32 kDa and 42 
kDa. Several P. falciparum proteins were identified that match these molecular weights and are 
alkylated by peroxide probes (Table 2), e.g. a thioredoxin-related protein of 24 kDa, a glideosome 
associated protein of 42.6 kDa, or the proteasome subunit beta type-6 of 32.7 kDa. The latter may 
be of interest since a recent study (Leann Tilley; MMV Meeting Oktober 2017) found artemisinin 
to act against the proteasome. 
We paid special attention to hits of about 50 kDa, since this was the size of the main band identified 
in P. faclciparum cultures treated with OZ277 and labeled with monoclonal antibodies against the 
adamantane portion of the ozonides (Jourdan et al., 2015). Three candidates were identified (Table 
2): V-type proton ATPase subunit H (53.8 kDa), ATP-dependent RNA helicase UAP56 (52.2 kDa) 
and plasmepsin III (51.7 kDa). Plasmepsin III is a likely target since it localizes to the food vacuole 
and was suggested to digest hemoglobin (Moura et al., 2009). Further proteins of the parasite's food 
vacuole that were alkylated by the peroxidic probes were aminopeptidase P, also involved in 
hemoglobin degradation (Rhageb et al., 2009), and multidrug resistance protein 1, a transporter in 
the digestive vacuolar membrane (Ding et al., 2011; Valderramos et al., 2006; Duraisingh et al., 
2005). Only one of the 45 identified alkylation targets (Table 2) was present in all the peroxide-
treated cultures, the EMP-like protein PFNF54_01699, a parasite protein thought to be exported to 
the membrane of the erythrocyte and to associate with its cytoskeleton (Pei et al., 2007; Senczuk et 
al., 2001). 
In conclusion, we show that the designed peroxide probes alkylate P. falciparum proteins in a 
peroxide-dependent manner, and that they possess alkylation signatures of distinct Western blot 
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bands and relatively small sets of target proteins. There was an overlap between the alkylation 
signatures of artemisinin and ozonides, but to a lesser degree than observed in a previous study 
(Ismail et al., 2016b). The presence of food vacuolar proteins among the alkylated targets, plasmepsin 
III in particular, supports the iron-dependent alkylation model. While we cannot presently say to 
what degree the observed protein alkylation signatures contribute to the antimalarial activity of the 
peroxides, we think that the identified sets of target proteins may hold a key to a better 
understanding of the mode of action of artemisinin and synthetic peroxides. 
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Material and Methods 
Parasite cultivation and drug sensitivity testing 
Asexual blood stages of P. falciparum strain NF54 (Origin: Airport, Netherlands; Provider MR4, 
MRA-1000) were cultivated in human erythrocytes by standard methods described previously 
(Dorn et al., 1995; Trager et al., 1976), maintained in humidified modular chambers in an 
atmosphere of 93% N2, 4% CO2 and 3% O2 at 37 °C. The medium consisted of RPMI 1640 
supplemented with 0.5% ALBUMAX® II, 25 mM Hepes, 25 mM NaHCO3 (pH 7.3), 0.36 mM 
hypoxanthine and 100 µg/mL neomycin (Snyder et al., 2007). The 50% inhibitory concentrations 
(IC50) were determined in vitro by quantifying the multiplication of P. falciparum via the 
incorporation of [3H]-hypoxanthine as described (Desjardins et al., 1979).  
 
Protein isolation 
Parasite cultures at 5% (v/v) hematocrit and 7-12.5% parasitemia were treated for 4 h with 1 µg/mL 
or 0.1 µg/mL OZ726, OZ727, AA2, OZ03, carbaOZ727, deoxyAA2 or artemisinin.  As control, 
parasites were treated with 0.1% DMSO. Cells were harvested by centrifugation and the cell pellets 
were resuspended in 0.3% saponin in PBS and incubated for 10 min on ice. The cells were washed 
three times with PBS and lysed in either 1.2% SDS plus EDTA-free protease inhibitor mixture 
tablets (Roche Applied Science) or in 50 μL of complete Ripa-Lysis buffer (20 mM Tris-HCl, pH 8.0, 
137 mM NaCl, 10% glycerol, 1% NP40, 2 mM EDTA, EDTA-free protease inhibitor mixture tablets 
(Roche Applied Science)). After brief sonication, the samples were centrifuged and extracts 
normalized for protein content using a BCA protein assay kit (Merck Millipore).  
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Click chemistry 
Azide-alkyne Huisgen cycloaddition reactions were performed using the Click-iT® Plus Alexa Fluor 
488 Picolyl Azide Toolkit (Life Technologies), using 1.25 µM biotin azide (Thermo Fisher Scientific) 
instead of the Alexa Fluor 488 azide. 150 µL Click-iT Plus reaction cocktail were added to 35 µL 
protein extract and incubated for 30 min. Proteins were precipitated with four volumes of cold 
acetone (-20°C), incubated at -20°C for 1h, and centrifuged for 10 min at 13148 g. Pellets were air-
dried for 15 min and resuspended in 1 ml 0.1% SDS in PBS with sonication. 
 
Western blot 
Resuspended protein samples were diluted 1:2 with 2x LDS sample buffer (50% 4x LDS sample 
buffer, Invitrogen; 20% mercaptoethanol; 30% H2O). Samples were heated at 95 °C for 10 min and 
loaded onto polyacrylamide gels (NuPAGE 4-12% bis-tris-polyacrylamide gels, Invitrogen). Gels 
were run in 1x MES SDS running buffer (Invitrogen) and transferred onto nitrocellulose membranes 
(0.2 µm pore size, Invitrogen). After blocking for 1 h in 3% milk powder in TBS-Tween pH 8.0, 
streptavidin-coupled horseradish peroxidase (Pierce, Thermo Fisher Scientific), diluted 1/500 in 
blocking solution (0.5% milk powder in TBS-Tween pH 8.0), was added and incubated for 1 h at 
RT. Membranes were washed four times with TBS-Tween, and Super Signal West Pico 
chemiluminescent substrate (Thermo Fisher Scientific) was added. Signals were detected after 5 min 
on Carestream Kodak Biomax light film (Sigma Aldrich).  
 
Sample preparation for mass spectometry 
Samples were prepared according to a recently published protocol (Turriziani et al., 2014). In brief, 
EDTA-free protease inhibitor mixture tablets (Roche Applied Science) were added to the samples 
and samples were incubated with 50 µL Pierce™ NeutrAvidin™ Agarose (Thermo Fisher Scientific; 
Product No. 29201) with rotation overnight at 4 °C. Samples were centrifuged and washed 3 times 
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with 1 ml 1% SDS in PBS, once with 0.1% SDS in PBS, once with 6 M Urea in ddH2O, once with 
PBS and once with ddH2O. Then, samples were washed 3 times with 700 µL 100 mM 
ammoniumbicarbonate. Next 100 µL elution buffer 1 (1.6 M urea, 100 mM ammoniumbicabonate, 
5 µg/ml trypsin) was added, samples were vortexed and incubated for 30 min on a thermomixer at 
27 °C at 1200 rpm. Samples were centrifuged and the supernatant was collected into a fresh tube. 
Then, 40 µL elution buffer 2 (1.6 M urea, 100 mM Ammoniumbicabonate, 1 mM tris(2-
carboxyethyl)phosphine) was added, samples were vortexed, centrifuged and the supernatant was 
added to the first eluate. This washing step was repeated once. Next, the tubes containing the 
supernatants were vortexed and incubated overnight at RT. Then, 40 µl of an aqueous iodoacetamide 
solution (5 mg/ml) was added, samples were vortexed and incubated in the dark for 30 min. 
Subsequently, samples were acidified with 170 µL 5% trifluoroacetic acid to a pH below 2. Next, 
peptides were cleaned up using C18 microspin columns (Harvard Apparatus, SEM SS18V) following 
the manufacturer’s instructions. Finally, peptides were dried under vacuum and stored at -80°C until 
further processing. 
 
Mass spectrometry and statistical analyses 
1 ug of peptides of each sample were subjected to LC–MS analysis using a dual pressure LTQ-
Orbitrap Elite mass spectrometer connected to an electrospray ion source (both Thermo Fisher 
Scientific) as described recently (Ahrné et al., 2016) with a few modifications. In brief, peptide 
separation was carried out using an EASY nLC-1000 system (Thermo Fisher Scientific) equipped 
with a RP-HPLC column (75 μm × 30 cm) packed in-house with C18 resin (ReproSil-Pur C18–AQ, 
1.9 μm resin; Dr. Maisch GmbH, Ammerbuch-Entringen, Germany) using a linear gradient from 
95% solvent A (0.15% formic acid, 2% acetonitrile) and 5% solvent B (98% acetonitrile, 0.15% 
formic acid) to 28% solvent B over 90 min at a flow rate of 0.2 μl/min. The data acquisition mode 
was set to obtain one high resolution MS scan in the FT part of the mass spectrometer at a resolution 
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of 120,000 full width at half-maximum (at m/z 400) followed by MS/MS scans in the linear ion trap 
of the 20 most intense ions using rapid scan speed. The charged state screening modus was enabled 
to exclude unassigned and singly charged ions and the dynamic exclusion duration was set to 30s. 
The ion accumulation time was set to 300 ms (MS) and 25 ms (MS/MS). 
For label-free quantification, the generated raw files were imported into the Progenesis QI software 
(Nonlinear Dynamics (Waters), Version 2.0) and analyzed using the default parameter settings. 
MS/MS-data were exported directly from Progenesis QI in mgf format and searched against a decoy 
database the forward and reverse sequences of the predicted proteome from Plasmodium falciparum 
(isolate NF54, UniProt, download date: 12/10/2015, total of 12,376 entries) using MASCOT (version 
2.4.1). The search criteria were set as follows: full tryptic specificity was required (cleavage after 
lysine or arginine residues); 3 missed cleavages were allowed; carbamidomethylation (C) was set as 
fixed modification; oxidation (M) as variable modification. The mass tolerance was set to 10 ppm for 
precursor ions and 0.6 Da for fragment ions. Results from the database search were imported into 
Progenesis QI and the final peptide measurement list containing the peak areas of all identified 
peptides, respectively, was exported. This list was further processed and statically analyzed using 
our in-house developed SafeQuant R script (Ahrné et al., 2016). The peptide and protein false 
discovery rate (FDR) was set to 1% using the number of reverse hits in the dataset.  
 
Data availability 
All mass spectrometry raw data files have been deposited to the ProteomeXchange Consortium 
(accession code PXDxxx, http://proteomecentral.proteomexchange.org, reviewer login: username: 
xxx, password: xxx) via the PRIDE partner repository (Vizcaino et al., 2013).  
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Table 2. All proteins that were significantly enriched in P. falciparum cultures treated with 100 ng/ml or 1000 ng/ml OZ726, OZ727 or AA2 over the DMSO-treated controls, minus the 
proteins that were also identified in the parent drug controls (artemisinin and OZ03) or in the nonperoxidic controls (deoxyAA2 and carbaOZ727). For unknown reasons, there were no 
significant hits in the 1000 ng/ml sample of OZ727 in comparison to the DMSO control (Table S1). 
 
UniProt ID Protein description 
MW 
[kDa] 
AA2 
100 
OZ726 
100 
OZ727 
100 
AA2 
1000 
OZ726 
1000 
PFNF54_01699 Conserved Plasmodium protein, unknown function  196.6 x x x x x 
PFNF54_01242 Eukaryotic translation initiation factor 3 subunit E, putative  61.4 x x    
PFNF54_02052 GTPase-activating protein, putative  56.5 x x    
PFNF54_00777 Glideosome associated protein with multiple membrane spans 2  42.6 x x    
PFNF54_04517 T-complex protein 1 subunit delta  58.0  x x   
PFNF54_01390 T-complex protein 1 subunit zeta  61.5  x x   
PFNF54_02843 Chromodomain-helicase-DNA-binding protein 1 homolog, putative  381.3  x x   
PFNF54_04470 Nuclear movement protein, putative  46.0  x x   
PFNF54_05640 Thioredoxin peroxidase 1  21.8  x x x x 
PFNF54_02310 Nucleoside transporter 2  67.6 x  x   
PFNF54_03725 Conserved Plasmodium protein, unknown function  122.8  x   x 
PFNF54_04135 V-type proton ATPase subunit H, putative  53.8  x    
PFNF54_05670 FACT complex subunit SSRP1, putative  58.8  x    
PFNF54_02736 RNA-binding protein, putative  106.3  x    
PFNF54_02383 Hsp70-like protein 75.1  x    
PFNF54_02720 Conserved Plasmodium protein, unknown function  14.5  x    
PFNF54_01130 FACT complex subunit SPT16, putative  132.7  x   x 
PFNF54_05278 Nascent polypeptide-associated complex subunit beta  19.4  x    
PFNF54_03483 Dynamin-like protein  96.4  x    
PFNF54_04789 Thioredoxin-related protein, putative  24.0 x   x x 
PFNF54_00257 ATP-dependent RNA helicase UAP56  52.2 x    x 
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PFNF54_02120 Histone S-adenosyl methyltransferase, putative  129.2 x   x  
PFNF54_05599 Conserved protein, unknown function  32.6 x     
PFNF54_03298 T-complex protein 1 subunit alpha  60.3 x     
PFNF54_01342 Conserved Plasmodium protein, unknown function  334.4   x   
PFNF54_01696 Importin-7, putative  145.5    x x 
PFNF54_03261 Spermidine synthase  36.6    x x 
PFNF54_03012 Casein kinase II subunit beta 28.4    x x 
PFNF54_03252 Prefoldin subunit alpha, putative  29.1    x x 
PFNF54_03153 Insulinase, putative  173.6    x x 
PFNF54_00668 V-type proton ATPase subunit B  55.8    x x 
PFNF54_00014 Nucleoside transporter 4  50.0     x 
PFNF54_04551 Conserved Plasmodium protein, unknown function  291.0     x 
PFNF54_03586 Eukaryotic translation initiation factor 5A  17.6     x 
PFNF54_02629 Proteasome subunit beta type-6, putative  32.6     x 
PFNF54_05054 Aminopeptidase P  90.1     x 
PFNF54_01342 Conserved Plasmodium protein, unknown function  334.4     x 
PFNF54_01192 Multidrug resistance protein 162.3     x 
PFNF54_04908 Plasmepsin III  51.7     x 
PFNF54_05266 60S Ribosomal protein L7-3, putative 32.7     x 
PFNF54_03239 Protein phosphatase, putative  34.5     x 
PFNF54_04191 V-type proton ATPase catalytic subunit A 68.6     x 
PFNF54_00552 T-complex protein 1 subunit epsilon 59.2     x 
PFNF54_02838 60S Ribosomal protein L30e, putative 11.8     x 
PFNF54_02025 Glutamate dehydrogenase, putative 160.4    x  
  
103 | P a g e  
 
Table 3. Hits identified herein that are also present in the published datasets by Wang et al. (2015) and Ismail et al. (2016a, 2016b). 
 
UniProt ID Protein description 
AA2 
100 
OZ726 
100 
OZ727 
100 
AA2 
1000 
OZ726 
1000 
Wang 
2015 
Ismail 
2016a,b 
PFNF54_04789 Thioredoxin-related protein, putative  x   x x x  
PFNF54_00257 ATP-dependent RNA helicase UAP56  x    x x  
PFNF54_02310 Nucleoside transporter 2  x  x   x  
PFNF54_05640 Thioredoxin peroxidase 1   x x x x x  
PFNF54_01696 Importin-7, putative     x x x  
PFNF54_03261 Spermidine synthase     x x x  
PFNF54_03153 Insulinase, putative     x x x  
PFNF54_02025 Glutamate dehydrogenase, putative     x  x  
PFNF54_04517 T-complex protein 1 subunit delta   x x   x  
PFNF54_01390 T-complex protein 1 subunit zeta   x x   x  
PFNF54_04908 Plasmepsin III      x x  
PFNF54_02838 60S ribosomal protein L30e, putative      x x  
PFNF54_01192 Multidrug resistance protein     x x x 
PFNF54_04191 V-type proton ATPase catalytic subunit A      x x x 
PFNF54_00668 V-type proton ATPase subunit B     x x  x 
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Supplementary Material 
 
Table S1. All significant hits obtained with chemical probes as compared to DMSO-treated P. falciparum control cultures. 
 
UniProt ID Protein description MW AA2 AA2 ART ART deoxyAA2 deoxyAA2 OZ726 OZ726 OZ727 OZ727 OZ03 OZ03 carbaOZ727 carbaOZ727
[kDa] 100 1000 100 1000 100 1000 100 1000 100 1000 100 1000 100 1000
PFNF54_01699  conserved Plasmodium protein, unknown function 196.6 X X X X X
PFNF54_01242  eukaryotic translation initiation factor 3 subunit E, putative 61.4 X X
PFNF54_02052  GTPase-activating protein, putative 56.5 X X
PFNF54_00777  glideosome associated protein with multiple membrane spans 2 42.6 X X
PFNF54_04517  T-complex protein 1 subunit delta 58.0 X X
PFNF54_01390  T-complex protein 1 subunit zeta 61.5 X X
PFNF54_02843  chromodomain-helicase-DNA-binding protein 1 homolog, putative 381.3 X X
PFNF54_04470  nuclear movement protein, putative 46.0 X X
PFNF54_05640  thioredoxin peroxidase 1 21.8 X X X X
PFNF54_02310  nucleoside transporter 2 67.6 X X
PFNF54_03725  conserved Plasmodium protein, unknown function 122.8 X X
PFNF54_04135  V-type proton ATPase subunit H, putative 53.8 X
PFNF54_05670  FACT complex subunit SSRP1, putative 58.8 X
PFNF54_02736  RNA-binding protein, putative 106.3 X
PFNF54_02383  heat shock protein 70 75.1 X
PFNF54_02720  conserved Plasmodium protein, unknown function 14.5 X
PFNF54_01130  FACT complex subunit SPT16, putative 132.7 X X
PFNF54_05278  basic transcription factor 3b, putative 19.4 X
PFNF54_03483  dynamin-like protein 96.4 X
PFNF54_04789  thioredoxin-related protein, putative 24.0 X X X
PFNF54_00257  ATP-dependent RNA helicase UAP56 52.2 X X
PFNF54_02120  histone S-adenosyl methyltransferase, putative 129.2 X X
PFNF54_05599  conserved protein, unknown function 32.6 X
PFNF54_03298  T-complex protein 1 subunit alpha 60.3 X
PFNF54_01342  conserved Plasmodium protein, unknown function 334.4 X
PFNF54_01696  importin-7, putative 145.5 X X
PFNF54_03261  spermidine synthase 36.6 X X
PFNF54_03012  casein kinase II beta chain 28.4 X X
PFNF54_03252  prefoldin subunit 5, putative 29.1 X X
PFNF54_03153  insulinase, putative 173.6 X X
PFNF54_00668  V-type proton ATPase subunit B 55.8 X X
PFNF54_00014  nucleoside transporter 4 50.0 X
PFNF54_04551  conserved Plasmodium protein, unknown function 291.0 X
PFNF54_03586  eukaryotic translation initiation factor 5A 17.6 X
PFNF54_02629  proteasome subunit beta type-6, putative 32.6 X
PFNF54_05054  aminopeptidase P 90.1 X
PFNF54_01342  conserved Plasmodium protein, unknown function 334.4 X
PFNF54_01192  multidrug resistance protein 1 162.3 X
PFNF54_04908  plasmepsin III 51.7 X
PFNF54_05266  60S ribosomal protein L7-3, putative 32.7 X
PFNF54_03239  protein phosphatase, putative 34.5 X
PFNF54_04191  V-type proton ATPase catalytic subunit A 68.6 X
PFNF54_00552  T-complex protein 1 subunit epsilon 59.2 X
PFNF54_02838  60S ribosomal protein L30e, putative 11.8 X
PFNF54_02025  glutamate dehydrogenase, putative 160.4 X
PFNF54_02028  1-cys peroxiredoxin 25.2 X
PFNF54_03743  cell cycle associated protein, putative 324.1 X X X X
PFNF54_01079  bifunctional dihydrofolate reductase-thymidylate synthase 371.7 X X X X X X X X X
PFNF54_05172  60S ribosomal protein L44 12.2 X X X X X X X
PFNF54_03313  antigen UB05 13.7 X X
PFNF54_03023  histone H4 11.5 X
PFNF54_01156  conserved Plasmodium protein, unknown function 22.7 X X X
PFNF54_01149  40S ribosomal protein S24 15.4 X
PFNF54_00991  deoxyribodipyrimidine photo-lyase, putative 129.2 X X X
PFNF54_03121  conserved Plasmodium protein, unknown function 33.9 X X X X X X
PFNF54_01036  40S ribosomal protein S9, putative 22.1 X
PFNF54_03241  tRNA (guanine-N(7)-)-methyltransferase, putative 35.6 X X
PFNF54_04551  conserved Plasmodium protein, unknown function 291.0 X X
PFNF54_00516  40S ribosomal protein S15A, putative 14.9 X X
59 15 13 1 0 6 0 24 29 16 0 10 2 0 0
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UniProt ID Protein description MW AA2 AA2 ART ART deoxyAA2 deoxyAA2 OZ726 OZ726 OZ727 OZ727 OZ03 OZ03 carbaOZ727 carbaOZ727
[kDa] 100 1000 100 1000 100 1000 100 1000 100 1000 100 1000 100 1000
PFNF54_01699  conserved Plasmodium protein, unknown function 196.6 X X X X X
PFNF54_01242  eukaryotic translation initiation factor 3 subunit E, putative 61.4 X X
PFNF54_02052  GTPase-activating protein, putative 56.5 X X
PFNF54_00777  glideosome associated protein with multiple membrane spans 2 42.6 X X
PFNF54_04517  T-complex protein 1 subunit delta 58.0 X X
PFNF54_01390  T-complex protein 1 subunit zeta 61.5 X X
PFNF54_02843  chromodomain-helicase-DNA-binding protein 1 homolog, putative 381.3 X X
PFNF54_04470  nuclear movement protein, putative 46.0 X X
PFNF54_05640  thioredoxin peroxidase 1 21.8 X X X X
PFNF54_02310  nucleoside transporter 2 67.6 X X
PFNF54_03725  conserved Plasmodium protein, unknown function 122.8 X X
PFNF54_04135  V-type proton ATPase subunit H, putative 53.8 X
PFNF54_05670  FACT complex subunit SSRP1, putative 58.8 X
PFNF54_02736  RNA-binding protein, putative 106.3 X
PFNF54_02383  heat shock protein 70 75.1 X
PFNF54_02720  conserved Plasmodium protein, unknown function 14.5 X
PFNF54_01130  FACT complex subunit SPT16, putative 132.7 X X
PFNF54_05278  basic transcription factor 3b, putative 19.4 X
PFNF54_03483  dynamin-like protein 96.4 X
PFNF54_04789  thioredoxin-related protein, putative 24.0 X X X
PFNF54_00257  ATP-dependent RNA helicase UAP56 52.2 X X
PFNF54_02120  histone S-adenosyl methyltransferase, putative 129.2 X X
PFNF54_05599  conserved protein, unknown function 32.6 X
PFNF54_03298  T-complex protein 1 subunit alpha 60.3 X
PFNF54_01342  conserved Plasmodium protein, unknown function 334.4 X
PFNF54_01696  importin-7, putative 145.5 X X
PFNF54_03261  spermidine synthase 36.6 X X
PFNF54_03012  casein kinase II beta chain 28.4 X X
PFNF54_03252  prefoldin subunit 5, putative 29.1 X X
PFNF54_03153  insulinase, putative 173.6 X X
PFNF54_00668  V-type proton ATPase subunit B 55.8 X X
PFNF54_00014  nucleoside transporter 4 50.0 X
PFNF54_04551  conserved Plasmodium protein, unknown function 291.0 X
PFNF54_03586  eukaryotic translation initiation factor 5A 17.6 X
PFNF54_02629  proteasome subunit beta type-6, putative 32.6 X
PFNF54_05054  aminopeptidase P 90.1 X
PFNF54_01342  conserved Plasmodium protein, unknown function 334.4 X
PFNF54_01192  multidrug resistance protein 1 162.3 X
PFNF54_04908  plasmepsin III 51.7 X
PFNF54_05266  60S ribosomal protein L7-3, putative 32.7 X
PFNF54_03239  protein phosphatase, putative 34.5 X
PFNF54_04191  V-type proton ATPase catalytic subunit A 68.6 X
PFNF54_00552  T-complex protein 1 subunit epsilon 59.2 X
PFNF54_02838  60S ribosomal protein L30e, putative 11.8 X
PFNF54_02025  glutamate dehydrogenase, putative 160.4 X
PFNF54_02028  1-cys peroxiredoxin 25.2 X
PFNF54_03743  cell cycle associated protein, putative 324.1 X X X X
PFNF54_01079  bifunctional dihydrofolate reductase-thymidylate synthase 371.7 X X X X X X X X X
PFNF54_05172  60S ribosomal protein L44 12.2 X X X X X X X
PFNF54_03313  antigen UB05 13.7 X X
PFNF54_03023  histone H4 11.5 X
PFNF54_01156  conserved Plasmodium protein, unknown function 22.7 X X X
PFNF54_01149  40S ribosomal protein S24 15.4 X
PFNF54_00991  deoxyribodipyrimidine photo-lyase, putative 129.2 X X X
PFNF54_03121  conserved Plasmodium protein, unknown function 33.9 X X X X X X
PFNF54_01036  40S ribosomal protein S9, putative 22.1 X
PFNF54_03241  tRNA (guanine-N(7)-)-methyltransferase, putative 35.6 X X
PFNF54_04551  conserved Plasmodium protein, unknown function 291.0 X X
PFNF54_00516  40S ribosomal protein S15A, putative 14.9 X X
59 15 13 1 0 6 0 24 29 16 0 10 2 0 0
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Table S2. Summary of Table S1, indicating the overlaps between the sets of obtained hits. 
 
 
AA2 AA2 ART ART deoxyAA2 deoxyAA2 OZ726 OZ726 OZ727 OZ727 OZ03 OZ03 carbaOZ727 carbaOZ727
100 1000 100 1000 100 1000 100 1000 100 1000 100 1000 100 1000
AA2 100 15 5 1 0 3 0 8 6 5 0 4 2 0 0
AA2 1000 13 1 0 1 0 4 11 4 0 2 1 0 0
ART 100 1 0 1 0 1 1 1 0 1 1 0 0
ART 1000 0 0 0 0 0 0 0 0 0 0 0
deoxyAA2 100 6 0 2 2 4 0 2 2 0 0
deoxyAA2 1000 0 0 0 0 0 0 0 0 0
OZ726 100 24 8 11 0 6 2 0 0
OZ726 1000 29 6 0 4 2 0 0
OZ727 100 16 0 6 2 0 0
OZ727 1000 0 0 0 0 0
OZ03 100 10 2 0 0
OZ03 1000 2 0 0
carbaOZ727 100 0 0
carbaOZ727 1000 0
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 Figure S1. Optimization of assay parameters as determined by Western blot. A) Different incubation times of 
P. falciparum cultures with 1000 ng/ml ozonide alkyne, exposure 10 s; B) Different concentrations of ozonide 
alkyne at 4 h drug incubation, exposure 30 s. Parasite cultures were lysed with Ripa-Lysis buffer (see Material 
and Methods for details). 
 
 
 
 Figure S2. Optimization of washing conditions of the neutravidin-coupled agarose beads after reaction with 
biotinylated peptides as determined by silver stain. P. falciparum cultures were incubated with 100 ng/ml AA2 
or 0.1% DMSO for 4 h. Protein extracts were prepared with 1.2% SDS in PBS. 
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 Figure S3. Optimization of washing conditions of the neutravidin-coupled agarose beads after reaction with 
biotinylated peptides as determined by Western blot. P. falciparum cultures were treated with 100 ng/ml AA2 
or 0.1% DMSO and extracts were prepared with 1.2% SDS in PBS. Exposure 1 min. 
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5. Discussion 
Artemisinin is an antimalarial of highest potency and tolerability. However, it also has drawbacks: 
As natural products, artemisinin and it derivatives suffer from poor availability and high costs. 
Furthermore, they have short in vivo half-lifes and are difficult to chemically modify and improve 
(White, 2008; Tilley et al., 2016). Vennerstrom reported in 2004 the development of synthetic 
peroxides, which should overcome the drawbacks of artemisinins (Vennerstrom et al., 2004). The 
next-generation ozonide OZ439 showed promising properties in clinical trials with a rapid parasite 
clearance, good safety profiles and a prolonged elimination half-life of 46-62 hours, in contrast to 
the first-generation ozonide OZ277 (Phyo et al., 2016; Möhrle et al., 2012). This raises hope for a 
single-dose treatment of OZ439 in combination with another drug to become an important new 
treatment for P. falciparum infections (Phyo et al., 2016; Möhrle et al., 2012; Mäser et al., 2010; 
Phillips et al., 2017). However, a prerequisite for any new antimalarial is activity against 
artemisinin-resistant P. falciparum isolates, which have been reported from South-East Asia since 
2006 and are the cause of the phenomenon of delayed parasite clearance after artemisinin treatment 
(Noedl et al., 2008; Dondorp et al., 2009). Several different mutations in the K13 propeller domain 
were found to be major determinants of artemisinin resistance (Chapter 1). Thereby individual point 
mutations in K13 were sufficient to induce enhanced parasite clearance half-lives of >5h after 
artemisinin treatment, indicating artemisinin resistance in P. falciparum isolates (Blasco et al., 2017; 
Straimer et al., 2015). It is suggested that ring stages become refractory to drug action and that these 
ring stages have an enhanced capacity to regulate cellular stress response to counteract the protein 
damage caused by artemisinin. Thereby the unfolded protein response or the ubiquitin/proteasome 
system, which serves as a regulated protein degradation system, are involved. But the exact function 
and mechanism of K13 mutations protecting ring-stages in not known (Blasco et al., 2017; Tilley et 
al., 2016, Wang et al., 2017). 
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The fear of cross-resistance of artemisinin-resistant parasites against synthetic peroxides 
overshadowed the superior pharmacological properties of OZ439, since both, artemisinins and 
synthetic peroxides, share the peroxide bridge essential for drug action (Kaiser et al., 2007). Hence, 
we undertook in vitro studies to test for potential cross-resistance of an artemisinin-resistant P. 
falciparum clinical isolate from Battambang (Cambodia) carrying a K13 mutation (Cam3.IR539T) 
against synthetic peroxides (Chapter 3). The mutation R539T was found to confer increased in vitro 
survival rates and delayed parasite clearance in patients after artemisinin treatment (Ariey et al., 
2014; Ménard et al., 2016; Straimer et al., 2015).  In Chapter 3 we showed that the artemisinin-
resistant clinical isolate had a 45-fold lower survival rate in vitro when exposed to OZ439 than to 
dihydroartemisinin, indicating no cross-resistance between the two antimalarial peroxides (Chapter 
3). Our finding was supported by other in vitro studies showing no cross-resistance of the clinical 
isolate Cam3.IIR539T and another clinical isolate carrying a C580Y mutation (Cam3.IIC580Y) against 
OZ439 (Straimer et al., 2017; Siriwardana et al., 2016). In addition, Yang et al. found that synthetic 
peroxides are more effective than dihydroartemisinin against early-ring stages when exposed for 
physiologically relevant periods (Yang et al., 2016). The ability of OZ439 to overcome artemisinin 
resistance was further supported by the finding that the median parasite clearance half-life in 
patients infected with P. falciparum parasites carrying mutations in K13 was only one hour longer 
than in patients with P. falciparum parasites lacking K13 mutations (Phyo et al., 2016). Together, 
all these facts raise hope that OZ439 is a promising drug candidate to overcome artemisinin 
resistance in combination with a partner drug. 
It was shown that the mode of action of synthetic peroxides involves the formation of carbon-
centered radicals, predominantly on the adamantane-portion of the ozonides (Vennerstrom et al., 
2004; Maerki et al., 2006). Therefore, the production of monoclonal antibodies raised against this 
adamantane-portion offered us the unique opportunity to investigate the alkylation signature of the 
synthetic peroxides OZ277 and OZ439. In Chapter 2 I showed that both monoclonal antibodies used 
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in this study bind specifically to the alkylation targets of OZ277 and OZ439 (Chapter 2). Since no 
protein bands were observed in a Western blot experiment using Babesia divergens treated with 
synthetic peroxides, an intraerythrocytic protozoan parasite that does not digest hemoglobin and 
therefore does not produce hemozoin, we could demonstrate that digestion of hemoglobin is 
essential for the activity of ozonides (Chapter 2; Zintl et al., 2003; Richier et al., 2006). This finding 
was in agreement with Kaiser et al., who showed that OZ277 was not active in vitro against B. 
divergens (Kaiser et al., 2007).  
In Chapter 4, I analysed the alkylation signatures of the newly synthesized alkyne OZ726 by mass 
spectrometry and identified aminopeptidase P and plasmepsin III, both suggested to be involved in 
hemoglobin catabolism, further supporting the iron-dependent alkylation hypothesis (Chapter 4). I 
could also show that the peroxide bridge in synthetic peroxides is essential for drug action, since 
carbaOZ727 and deoxyAA2 showed no activity in vitro against P. falciparum NF54 and no protein 
alkylation was found in Western blot experiments with the nonperoxidic analogues OZ727 and AA2 
(Chapter 4). Further, mass spectrometry with carbaOZ727 and deoxyAA2 identified only four hits 
with deoxyAA2, while no hit was found in parasite cultures treated with carbaOZ727 (Chapter 4). 
In addition to the alkylation of heme which was described by Creek (Creek et al., 2008), I showed 
here that several other parasite proteins were alkylated by OZ277 and OZ439 (Chapter 2). This 
alkylation signature was further investigated by the establishment and application of the click 
chemistry approach using novel synthesized alkynes of artemisinin and synthetic peroxides. I 
identified 47 alkylated proteins in P. falciparum after treatement with OZ726, OZ727 or AA2 for 4 
h. One of these proteins, PFNF54_01699, was found to be most promising, since it was found in all 
samples (except 1000 ng/ml OZ727, which did not return a single hit). This protein is suggested to 
be an erythrocyte membrane protein (EMP)-like protein, a parasite protein thought to be exported 
to the RBC membrane (Pei et al., 2007; Senczuk et al., 2001). It appears there at the later stages of 
the parasite life cycle (Pei et al., 2007; Senczuk et al., 2001). P. falciparum EMP 1 mediates the 
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adhesion of the infected RBCs to the human vascular endothelium and is therefore important in the 
host-pathogen interaction (Pei et al., 2007; Senczuk et al., 2001; Sampaio et al., 2017). But further 
studies will be needed to characterize this alkylated protein.  
Another protein of the alkylation signature of OZ726 was the multidrug resistance protein 1 
(MDR1), an ABC transporter located in the digestive vacuole membrane (Blasco et al., 2017; 
Rohrbach et al., 2006). PfMDR1 was found to be linked to the sensitivity of P. falciparum to several 
antimalarial drugs (Ding et al., 2010). Thereby, partial but insufficient associations between 
mutations in PfMDR1 and chloroquine resistance were found (Duraising et al., 2005, Valderramos 
et al., 2006). Further, it was shown that increased copy numbers of PfMDR1 resulted in decreased 
in vitro susceptibility to mefloquine, quinine, halofantrine and artemisinin (Valderramos et al., 
2006; Sidhu et al., 2006).  
In 1994 Asawamahasakda identified four major protein bands (25kDa, 50kDa, 65kDa and >200kDa) 
and two minor ones (32kDa and 42kDa) with radiolabelled dihydroartemisinin. I have observed 
similar protein bands, except for the >200kDa band, when using the newly synthesized alkyne AA2 
in Western blots. The same pattern was also observed with either OZ726 or OZ727 (Chapter 4). The 
antibody studies also revealed a prominent protein band at 50 kDa in rings and schizonts treated 
with either OZ277 or OZ439 (Chapter 2). All these findings support the data of Asawamahasakda 
(Asawamahasakda et al., 1994). In addition, I found different proteins with the same identified 
masses than Asawamahasakda (Asawamahasakda et al., 1994) in the mass spectometry experiments 
when identifying the alkylation signatures of the synthetic peroxides and artemisinin-alkynes (as 
discussed in Chapter 4). 
Next, we could show that protein alkylation by OZ277 takes place in the cytoplasm and other 
structures such as the nucleus and the food vacuole (Chapter 2). This alkylation signature was similar 
to the ultrastructural autoradiographic studies performed by Maeno, where radiolabeled 
dihydroartemisinin and artemisinin located to the food vacuole, mitochondria and nuclear 
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membranes (Maeno et al., 1993). Other studies showed that TAMRA-labeled OZ277 was found in 
the cytosol or in the food vacuole (Uhlemann et al., 2007). In addition, it was found that artemisinin 
causes the disruption of the digestive vacuole membrane and that the food vacuole is an important 
site of synthetic peroxide action (Crespo et al., 2008). By analysing alkylation signatures of synthetic 
peroxides and artemisinin with mass spectrometry, we identified various proteins located to the 
cytoplasm, nucleus or food vacuole (Chapter 4).   
When we compared our identified alkylation signatures of synthetic peroxides and artemisinin to 
the recently observed data of Wang, who had also used a click chemistry approach with newly 
synthesized, but structurally slightly different artemisinin alkyne, we obtained 14 identical proteins, 
6 of which previously proposed as antimalarial drug targets (Wang et al., 2015). In contrast, click 
chemistry studies with synthetic peroxides and artemisinin performed by Ismail et al. did not show 
such a high degree of overlap (Ismail et al., 2016a and 2016b). This could be due to the use of 
trophozoites only compared to mixed parasite cultures used in our experiments, or because of 
prolonged drug incubation time (6 h in Ismail et al., 2016a and 2016b compared to 4 h in Chapter 
4). To further investigate the variation of identified alkylation signatures in different studies (Wang 
et al., 2015, Ismail et al., 2016a and 2016b; Chapter 4), one should use more stringent criteria, such 
as the use of highly synchronized parasite stages (rings, trophozoites or schizonts), identical drug 
incubation times and identical parasitemia. 
We demonstrated an overlap between the alkylation signatures of synthetic peroxides and 
artemisinin, but we did not observe such a high identity, i.e. 90%, as Ismail (Ismail et al., 2016b; 
Chapter 4). Our results strengthen the hypothesis that artemisinins and synthetic peroxides have a 
similar, but not identical mode of action (Vennerstrom et al., 2004; Jefford, 2001; Kaiser et al., 2007).  
Since our approach using alkynes with click chemistry worked well, a next step could be the 
investigation of alkylation signatures of synthetic peroxides and artemisinin in artemisinin-resistant 
P. falciparum strains compared to artemisinin-susceptible strains. Thereby one could identify the 
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differences in alkylation patterns in relation to artemisinin resistance and possibly shed light on the 
mechanism of artemisinin resistance.  
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6. Conclusion 
In conclusion, I could show that OZ277 and OZ439 localize to the cytoplasm of P. falciparum and 
other structures such as the nucleus and the food vacuole. I have identified the alkylation signatures 
of both, artemisinin and synthetic peroxides by using a click chemistry approach with newly 
synthesized alkynes. Further we could demonstrate that there is no cross-resistance between 
artemisinin and OZ439 in a Kelch-13 mutant P. falciparum field isolate. Further studies will be 
needed to investigate the importance of the most prominent identified alkylation target 
(PFNF54_01699) for drug action and identify the mechanism of artemisinin resistance to ensure 
that OZ439 remains a promising drug candidate that will overcome artemisinin resistance in 
combination with a partner drug. 
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